Article

Synthesis and Characterization of Gefitinib and Paclitaxel Mono and Dual Drug-Loaded Blood Cockle Shells (Anadara granosa)-Derived Aragonite CaCO₃ Nanoparticles

S. Chemmalar ¹, ², Abdul Razak Intan-Shameha ¹, ², *, Che Azurahanim Che Abdullah ³, ⁴, ⁵, Nor Asma Ab Razak ¹, ², Loqman Mohamad Yusof ⁶, Mokrish Ajat ¹, ², N. S. K. Gowthaman ⁷ and Md Zuki Abu Bakar ¹, ²

Abstract: Calcium carbonate has slowly paved its way into the field of nanomaterial research due to its inherent properties: biocompatibility, pH-sensitivity, and slow biodegradability. In our efforts to synthesize calcium carbonate nanoparticles (CSCaCO₃NP) from blood cockle shells (Anadara granosa), we developed a simple method to synthesize CSCaCO₃NP, and loaded them with gefitinib (GEF) and paclitaxel (PTXL) to produce mono drug-loaded GEF-CSCaCO₃NP, PTXL-CSCaCO₃NP, and dual drug-loaded GEF-PTXL-CSCaCO₃NP without usage of toxic chemicals. Fourier-transform infrared spectroscopy (FTIR) results reveal that the drugs are bound to CSCaCO₃NP. Scanning electron microscopy studies reveal that the CSCaCO₃NP, GEF-CSCaCO₃NP, PTXL-CSCaCO₃NP, and GEF-PTXL-CSCaCO₃NP are almost spherical nanoparticles, with a diameter of 63.9 ± 22.3, 83.9 ± 28.2, 78.2 ± 26.4, and 87.2 ± 26.7 (nm), respectively. Dynamic light scattering (DLS) and N₂ adsorption-desorption experiments revealed that the synthesized nanoparticles are negatively charged and mesoporous, with surface areas ranging from ~8 to 10 (m²/g). Powder X-ray diffraction (PXRD) confirms that the synthesized nanoparticles are aragonite. The CSCaCO₃NP show excellent alkalinization property in plasma simulating conditions and greater solubility in a moderately acidic pH medium. The release of drugs from the nanoparticles showed zero order kinetics with a slow and sustained release. Therefore, the physico-chemical characteristics and in vitro findings suggest that the drug loaded CSCaCO₃NP represent a promising drug delivery system to deliver GEF and PTXL against breast cancer.

Keywords: calcium carbonate nanoparticles; blood cockle shells; mesoporous; gefitinib; paclitaxel; mono drug loading; dual drug loading; XRD; FTIR

1. Introduction

Breast cancer accounts for almost one in four cancer cases in women worldwide [1]. According to the Global Cancer Observatory (GLOBOCAN), in the year 2020, the incidence
of breast cancer in women was 2,261,419 (11.7%) and the mortality was 684,996 (6.9%) [2]. The molecular mechanisms of breast cancer are complex, but three main classes of breast cancer have been identified, namely progesterone positive (PR+) or estrogen receptor-positive (ER+), human epidermal receptor-positive (HER+), and triple negative breast cancer (TNBC), where TNBC lacks the ER, PR, and HER [3]. Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic kinase activity and its overexpression has been detected in 30% to 60% of human breast cancer biopsies, being indicative of a poor prognosis [4]. Overexpression of the HER 2 receptor has been noticed in a significant number of cases of breast cancer [5], and it activates ligand-dependent stimulation of the kinase domain, resulting in the unprompted formation of dimers. HER 2 receptors’ capacities to potentiate signaling of HER 1 create potentiated growth stimuli that lead to stimulation of further intracellular pathways, which in turn maintain the explosive cell proliferation rates associated with the tumor. Hence, a rational choice of treatment for EGFR-expressing breast cancers would be to inhibit the EGFR-driven autocrine pathway. AstraZeneca’s ZD 1839, a low-molecular-weight (446.9) synthetic anilinoquinazoline, also called gefitinib or Iressa® [6,7], is a great choice for incorporating into chemotherapy since it is a selective, reversible inhibitor of EGFR tyrosine kinase [8,9]. Gefitinib (GEF) is structurally similar to ATP and has a higher affinity to ATP site in the clefts of the EGFR than ATP itself [7]. The inhibition of kinase has several effects, including cell cycle arrest, induction of apoptosis, inhibition of invasion and metastasis of tumor cells, and finally, augmentation of the antitumor effects of chemotherapy/radiation [10].

Conventional chemotherapy has been used in the clinical setting for many decades, although it poses the problems of drugs simply diffusing after they are administered and spreading freely throughout the body. This exposes healthy cell to the drugs, and results in obnoxious side-effects. Besides, only a small amount of the dosage administered reaches the actual tumor to elicit a therapeutic response [11,12]. Over the past decades, there has been a shift in focus towards nanotechnology and nanomedicine for cancer therapy since nanomedicines can overcome the lack of specificity of conventional chemotherapeutic agents, reduce the overall systemic toxicities, and help in delivering the payload to the tumor site safely. The dogma behind nanomedicines against cancer is the enhanced permeability retention effect (EPR). This is because tumors have leaky vasculature due to the sustained tumor angiogenesis and the tumor contains underdeveloped lymphatic drainage [13], which facilitates the passive directing of nanoparticles to the tumor [12]. Calcium carbonate is one of the inorganic compounds which worked its way into the field of nanomaterial research due to its inherent properties of availability, biocompatibility, pH-sensitivity, and slow biodegradability [14–16]. Calcium carbonate nanoparticles decompose slowly at the normal physiological pH (7.4) while it displays a faster decomposition in the acidic pH (<6.5) typical of the tumor environment [17]. Tumor cell death was achieved without any toxicity with the administration of calcium carbonate nanoparticles [18]. De novo synthesized CaCO₃ nanoparticles alkalinized the tumor microenvironment and shrank the tumor [19]. One of Nature’s well-known reserves of calcium carbonate are seashells. The shells are formed due to the bio mineralization process and are 95–99% comprised of calcium carbonate [20–22]. Calcium carbonate can be of six types, where the aragonite and calcite forms are the most widely produced in a biological setup [23]. The present study aims at developing an eco-friendly and biocompatible nanoparticulate anticancer drug from the shells of blood cockles (Anadara granosa), a marine bivalve organism that grows along the shallow waters of the coastline surrounding Malaysia. Blood cockles are a staple in the diet of Malaysians and millions of tons of shell food waste is currently being dumped into the environment, due to the increase of shellfish aquaculture. Recycling shell waste in various avenues will form the best solution to overcome the environmental pollution issue and improve sustainable living [24]. Shell wastes have been utilized in various applications such as in wastewater decontamination, as a soil conditioner, feed additive [25,26], and as a liming agent in construction.
Drug delivery systems where drugs or active principles are loaded into nanocarriers are very different from conventional drug delivery systems. Combination therapy is the current trend for cancer treatment, and the usage of nanomedicines in clinical settings is still in its infancy. Combining both these technologies will yield better chemotherapeutic systems, serving as the “magic pill” for cancer patients. The mode of action and toxicity profile of gefitinib compared to traditional cytotoxic drugs and radiation therapy provided an ideal rationale for using is in combination with conventional cytotoxic drugs to achieve additive or synergistic anticancer effects [27]. Combination therapy came into use in chemotherapy because of various factors that include overcoming drug resistance and multitargeted treatments for disturbing multiple nodes of pathways of interest for better treatment outcomes [28]. Synergistic and potentiated drug combinations like GEF and paclitaxel (PTXL) will help achieve one or more promising outcomes: improved efficacy, decreased dosage, and delayed development of drug resistance. Pharmacodynamically synergistic drug combination due to anti-counteractive actions—different targets of cross-talking pathways have been observed in different breast cancer cell lines. It was found that GEF produces anticancer effects, which assists the counteractive EGFR-hypoxia crosstalk in resisting PTXL pro-apoptotic property [29]. In vitro and in vivo studies with various cancer cell lines [30], has shown synergism between GEF and PTXL [31]. Considering all the beneficial properties of CSCaCO$_3$NP and the synergistic relationship of GEF and PTXL, this study was designed to load GEF and PTXL into CSCaCO$_3$NP to be used for intra-tumor or peri-tumor administration against breast cancer. This is the one-of-a-kind study where this drug combination is loaded on pH-dependent CSCaCO$_3$NP which would serve not only as a carrier but also as a local alkalizer to bring down the pH of the tumor microenvironment. Since higher hydrogen ion concentration in the tumor microenvironment has been correlated to increased tumor growth, local invasion, and metastasis [32], buffering of the tumor microenvironment has pathological effects on tumor cells. Moreover, PTXL and GEF are hydrophobic drugs and PTXL requires a solubilizer such as Cremophor EL which adds to the adverse effects faced by the patients. GEF needs to be taken per-os every 24 h. Hence designing a drug system which will carry the payload to the tumor site without any loss will mitigate the adverse effects caused by conventional chemotherapy. The biogenic calcium carbonate nanoparticles derived from the blood cockle shells have shown promising results in delivering chemotherapeutic drugs [14,15,33]. Various drug-loaded calcium carbonate nanoparticles have been synthesized with hydrophilic drugs [33–36], hydrophobic drugs [37], bioactive proteins [36], hormones [38], antibiotics [39,40], nucleic acids [41] to hybrids of alginate/CaCO$_3$ with DOX and PTXL [42], and heparin/CaCO$_3$/CaP nanoparticles [43]. Conventional drugs with lower solubility such as GEF and PTXL when loaded onto the pH-dependent CSCaCO$_3$NP, characterization becomes vital in the path of new drug development. Adequate testing as per the National Characterization Laboratory (NCL) guidelines must be followed [44].

For the first time, we have synthesized calcium carbonate nanoparticles derived from shells of the blood cockles using Tween 80 and mechanical dry ball milling. We also have developed a method to load the drugs GEF and PTXL onto CSCaCO$_3$NP to synthesize the novel mono drug-loaded GEF-CSCaCO$_3$NP and PTXL-CSCaCO$_3$NP and novel dual drug-loaded GEF-PTXL-CSCaCO$_3$NP. To quantify the concentration of drug that is loaded onto the nanoparticles, a simple UV-Vis spectrophotometry assay was developed. A method for the simultaneous estimation of GEF and PTXL was developed and validated for the first time. We have investigated the various physicochemical characteristics of the synthesized nanoparticles. The alkalizing and solubilizing properties of CSCaCO$_3$NP and the drug release kinetics of GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL-CSCaCO$_3$NP in various pH were determined. Also, we have demonstrated that GEF and PTXL can be loaded onto the inorganic CSCaCO$_3$NP, which have unique and advantageous physicochemical properties suitable to be used against breast cancer in future studies.
2. Materials and Methods

2.1. Materials and Reagents

GEF and PTXL (Gold Biotechnology, St. Louis, MO, USA), DMSO (Fisher Scientific U.K. Limited, Loughborough, UK), Tween 80 (R & M Marketing, Essex, UK), deionized water of HPLC grade with a resistance of 18.2 cm MΩ was obtained from a Milli-Q integral Water Purification System (Type I) for Ultrapure water (Merck KGaA, Darmstadt, Germany), double beam UV-Vis spectrophotometer (1650PC, Shimadzu Europe, Duisburg, Germany), high-speed centrifuge (Optima XPN, Beckman Coulter Life Sciences, Indianapolis, IN, USA), magnetic stirrer (WiseStir® Systematic Multi-Hotplate Stirrer, Dhaian Scientific®, Gangwon-do, Korea), hot air oven (UM500, Memmert GmbH+ Co.KG, Schwabach Germany), programmable ball miller (BML-6", Dhan Scientific), filter paper (Filtres Fioroni, Ingré, France), Field emission scanning electron microscope (Nova™ NanoSEM 230, FEI, Hillsboro, OR, USA), carbon-coated copper grid (Sigma-Aldrich, St. Louis, MO, USA), Energy dispersion X-ray (EDX) spectroscopy (X-max EDS, Oxford Instruments, Abingdon, UK), Zetasizer Nano ZS (Ver.7.11; Malvern Instruments Ltd., Malvern, UK), XRD (Shimadzu XRD-6000 powder diffractometer), FT-IR (Spectrum 100; Perkin Elmer, Shelton, CT, USA), Tristar II Plus (Micromeritics, Norcross, GA, USA), dialysis tubing cellulose membrane (typical molecular weight cut-off = 14,000, Sigma Aldrich, Merck KGaA, Darmstadt, Germany), shaker incubator (Hybaid Maxi 14, Thermo Fischer Scientific, Guldensporen-park, Merelbeke, Belgium) pH meter (LAQUA PH1100, Horiba, Minami-ku, Kyoto, Japan), nitric acid 65% for analysis EMSURE® (Merck KGaA, Darmstadt, Germany), hydrogen peroxide 35% (R & M Marketing, Essex, UK), PBS tablets (MP Biomedicals LLC, Santa Ana, CA, USA), Albumin from bovine serum (>96% GE, 05473, Fluka, Merck KGaA, Darmstadt, Germany), Atomic absorption spectrometer (900T, Perkin Elmer, Waltham, MA, USA).

Anadara granosa Linnaeus, 1758 (Mollusca, Bivalvia, Arcidae) were sourced from the local market in Serdang, Malaysia.

2.2. Synthesis of CSCaCO₃NP, GEF-CSCaCO₃NP, PTXL-CSCaCO₃NP, and GEF-PTXL-CSCaCO₃NP

2.2.1. Synthesis of CSCaCO₃NP from Cockle Shells Using Tween 80 and Ball Milling

The synthesis of CSCaCO₃NP comprises of two steps (Steps 1 and 2 of Figure 1). The first step was the synthesis of micron aragonite calcium carbonate (MAC) powder from blood cockle shells (Step 1 of Figure 1) [45]. The synthesis of nanoparticles is as per the step 2 of Figure 1. It entailed placing 2 g of the 75-µm of CSCaCO₃ powder and the addition of 20 mL of deionized water. The concoction was sonicated for fifteen minutes. Then 1 mL of Tween 80 was added, and the suspension was stirred at 1100 rpm with a magnetic stirrer bar for 2 h at room temperature. The obtained suspension was filtered using filter paper. The filtrate was centrifuged for 10 min at 14,000 rpm, and the supernatant was discarded. The pellet was dispersed upon the addition of 20 mL deionized water and then washed twice with deionized water. The collected nanoparticles were dried in an oven at 50 °C for 48 h. Upon drying, the nanoparticle was added to the dry milling container (8 × 11 cm). Milling was carried out using a programmable ball miller with a 10:1 ball to powder ratio, with ceramic balls (eight balls of 1.6 cm diameter and two balls of 2.5 cm diameter). This jar was placed on a programmable ball miller and operated at 120 rpm for 120 h. The resultant CSCaCO₃NP was then stored in an oven at 50 °C.
Figure 1. Schematic diagram showing the step-by-step synthesis of Blood cockle shell derived CaCO$_3$ nanoparticles. Step 1: Transformation of blood cockle shells into MAC, Step 2: Synthesis of CSCaCO$_3$NP from MAC, and Step 3: Synthesis of Mono drug-loaded GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and dual drug-loaded GEF-PTXL-CSCaCO$_3$NP. MAC, micron-size aragonite calcium carbonate particles; DI, Deionized water; CSCaCO$_3$NP, Blood cockle shell derived CaCO$_3$ nanoparticles; GEF, Gefitinib; PTXL, Paclitaxel; GEF-CSCaCO$_3$NP, GEF loaded Blood cockle shell derived CaCO$_3$ nanoparticles; PTXL-CSCaCO$_3$NP, PTXL loaded Blood cockle shell derived CaCO$_3$ nanoparticles and GEF-PTXL-CSCaCO$_3$NP, GEF and PTXL loaded Blood cockle shell derived CaCO$_3$ nanoparticles.

2.2.2. Synthesis of GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL-CSCaCO$_3$NP

GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL-CSCaCO$_3$NP were prepared by the following method (Step 3 of Figure 1). Three groups were devised to determine the perfect combination of drugs and CSCaCO$_3$NP. The experimental grouping is shown in Table 1. CSCaCO$_3$NP suspension was prepared with 0.05% Tween 80 buffer and DMSO in a 50:50 ratio. As per the groups, the drug dissolved in DMSO was added into the suspension drop by drop. The loading of drugs was achieved by continuous stirring at 200 rpm overnight at room temperature in a dark environment. The individual suspensions were centrifuged at 14,000 RPM for 10 min, followed by washing the pellet with deionized water and drying. The supernatants of mono and dual-drug loaded nanoparticles were collected and measured using a UV-Vis spectrophotometer to determine the amount of un-entrapped GEF and PTXL. All experiments were carried out in triplicate.
Table 1. Experimental design for synthesizing drug-loaded CSCaCO₃ NP.

| Sample                  | Drug                        | Drug (µg) | Solvent (mL) | CSCaCO₃ NP (µg) |
|-------------------------|-----------------------------|-----------|--------------|-----------------|
| GEF1-CSCaCO₃ NP         | GEF                         | 400       | 3            | 10,000          |
| GEF2-CSCaCO₃ NP         | GEF                         | 400       | 3            | 15,000          |
| GEF3-CSCaCO₃ NP         | GEF                         | 400       | 3            | 20,000          |
| PTXL1-CSCaCO₃ NP        | PTXL                        | 400       | 3            | 10,000          |
| PTXL2-CSCaCO₃ NP        | PTXL                        | 400       | 3            | 15,000          |
| PTXL3-CSCaCO₃ NP        | PTXL                        | 400       | 3            | 20,000          |
| GEF1-PTXL1-CSCaCO₃ NP   | GEF+PTXL                    | 400 + 200 | 3            | 10,000          |
| GEF2-PTXL2-CSCaCO₃ NP   | GEF+PTXL                    | 400 + 200 | 3            | 15,000          |
| GEF3-PTXL3-CSCaCO₃ NP   | GEF+PTXL                    | 400 + 200 | 3            | 20,000          |

1 All the samples were maintained at the same temperature, and the drug loading was executed following a simple stirring process; the solvent utilized was DMSO+0.05% Tween80 buffer (1:1 ratio). CSCaCO₃ NP, Blood cockle shell derived CaCO₃ nanoparticles; GEF, Gefitinib; PTXL, Paclitaxel; GEF-CSCaCO₃ NP, GEF loaded Blood cockle shell derived CaCO₃ nanoparticles; PTXL-CSCaCO₃ NP, PTXL loaded Blood cockle shell derived CaCO₃ nanoparticles and GEF-PTXL-CSCaCO₃ NP, GEF and PTXL loaded Blood cockle shell derived CaCO₃ nanoparticles.

2.3. Physicochemical Characterization of CSCaCO₃ NP, GEF-CSCaCO₃ NP, PTXL-CSCaCO₃ NP and GEF-PTXL-CSCaCO₃ NP

2.3.1. UV-Vis Spectrophotometry

Absorbance measurements were made using a double beam ultraviolet-visible spectrophotometer (Shimadzu 1650PC) at the wavelength range: 200–400 nm at a scan speed of 0.1 nm and with a constant slit width of 2.0 nm. The stock solution of GEF (20 mg/mL) was prepared by adding 10 mL of DMSO to 200 mg of GEF and sonicating for 5 min to ensure complete solubilization. The stock solution of PTXL (10 mg/mL) was prepared by adding 10 mL of DMSO to 100 mg of PTXL and sonicating for 5 min to ensure complete solubilization. DMSO was used without any further dilution. Tween 80 buffer was prepared by adding 10 µL of Tween 80 to 20 mL deionized water and sonicating for 5 min. A combination of DMSO and Tween 80 buffer (50:50) was used as the solvent in all the experiments. The stock solutions were measured and added to the solvent mixture such that the final concentration is 2.5–25 µg/mL for GEF and 10–90 µg/mL for PTXL, were obtained. In the dual drug system, 2.5–20 µg/mL for GEF and 1.25–10 µg/mL for PTXL were mixed in various concentrations, but the ratio of 2:1 was maintained for GEF: PTXL throughout. The blank used for these measurements was the solvent mixture without the drug. The working standard solutions were mixed and scanned in the UV range from 200 nm through 400 nm to determine the absorption maxima (λmax). The sample volume used was 4 mL, and measurements were taken at room temperature. Various concentrations of GEF, PTXL, and GEF+PTXL were assayed. The absorbances of the resulting solutions were measured at 332 and 248 nm for GEF and PTXL. For the dual drug admixture, GEF and PTXL were measured at 332 and 248 nm. Drug interaction studies were carried out. The procedure was repeated thrice, and the mean absorbances were calculated.

The concentrations obeying the Beer-lambert law were found and fitted for calibration with the OriginPro 9.0 program (OriginLab Corporation, Northampton, MA 01060, USA). The amount of GEF and PTXL loaded onto the calcium carbonate nanoparticles was determined by measuring the absorbance of the resulting supernatant obtained after centrifugation following the loading of drugs (From method 2.2.2). The unknown concentration was determined using the OriginPro 9.0 program. The entrapment efficiency (EE%) and loading content (LC%) was determined as per the formula [38]. The method was validated according to the International Conference on Harmonization Q2(R1) guidelines [46]. The analytical performance criteria which were tested for this method validation: linearity, recovery (%), precision, and sensitivity.
2.3.2. Field Emission Scanning Electron Microscopy (FESEM), and Energy Dispersion X-ray (EDX) Spectroscopy

For FESEM, the sample was dispersed onto 12 mm diameter aluminium sample holders using conductive carbon paint and then sputter-coated with a platinum layer under vacuum. This sample holder was then installed into the FESEM and examined. The elemental composition of the CSCaCO$_3$NP, GEF, PTXL, GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL-CSCaCO$_3$NP was determined using Energy dispersion X-ray (EDX) spectroscopy. We analyzed the images using ImageJ software (ImageJ 1.52a, National Institutes of Health, USA), and the data was processed with GraphPad Prism 8.0.2 (San Diego, CA, USA).

2.3.3. BET and BJH Analysis with N$_2$ Physisorption Isotherms

For N$_2$ adsorption and desorption experiments, the sample was initially outgassed at 90 °C for 60 min; Nitrogen adsorption and desorption at 77 K was carried out with a Micromeritics Tristar II Plus system. Based on the absorption and desorption isotherm at a relative pressure range of (P/P$_0$) from 0.01 to 0.991 fractions, the data generated were analyzed using the Brunauer-Emmett-Teller (BET) method and Barrett-Joyner-Halenda (BJH) models. We determined the BET specific surface area and BJH mean pore size from the isotherms.

2.3.4. Dynamic Light Scattering

For zeta potential (ζ-potential) and hydrodynamic size analysis, 0.4 mg of each sample of CSCaCO$_3$NP, GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL-CSCaCO$_3$NP was dispersed in 15 mL of deionized water and sonicated for 30 min. The sample to be analyzed was again double diluted with deionized water. For analysis of pure drugs, was dissolved in 20 mL of phosphate buffered saline (PBS) of pH 7.4 with 1% Tween 80 was used to dissolve 2 mg of GEF and 1 mg of PTXL, respectively. This solution was further diluted with PBS before the measurements. The sample was injected into disposable cuvettes and placed inside the Zetasizer Ver. 7.11 Nano ZS system. The hydrodynamic diameter was obtained from the intensity distribution using software version 2.2. We carried out three independent experiments to get the average hydrodynamic diameter and zeta potentials. The polydispersity index was measured along with the hydrodynamic diameter readings.

2.3.5. Powder X-ray Diffraction (PXRD) and Fourier-Transform Infrared Spectroscopy (FTIR)

PXRD patterns were obtained using the Shimadzu XRD-6000 powder diffractometer with Cu Kα (λ = 1.540562 Å) as the X-ray source. The samples were scanned at the step size of (° 2 Th.) 0.033 and scan step time (s) of 19.685 with diffraction angles ranging from 4.0207° to 89.9527° a voltage of 40 kV and current of 40 mA. We analyzed the obtained PXRD data with the X’Pert HighScore Plus 2.2 program using search-match operations with the Inorganic Crystal Structure Database (ICSD). The crystallite size D (Å) was determined using the Scherrer equation. Vesta software was used for creating the crystallographic model. For FTIR, the samples were analyzed using the Fourier infrared spectrophotometer (Model 100 series, Perkin Elmer) using the KBr pellet method as described [47], over the range of 4000 to 400 cm$^{-1}$ at a 2 cm$^{-1}$ resolution and averaging 64 scans. We analyzed the obtained data using the KnowItAll Informatics System 2020 (Bio-Rad, John Wiley & Sons, Inc., Hoboken, NJ, USA). The chemical structures were drawn using ChemBioDraw Ultra 12.0 (CambridgeSoft, Perkin Elmer, Shelton, CT, USA).

2.3.6. In Vitro Release Studies of GEF and PTXL

The in vitro drug release studies of GEF and PTXL were carried out in PBS with 0.2% (v/v) Tween 80 at pH 6.5, 5.6, and 7.4 at 37 °C by the dialysis method [48]. Two mL of PBS containing GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL CaCO$_3$NP containing 800 µg, 800 µg and 800 µg + 400 µg of GEF, PTXL, and GEF+PTXL, respectively, was
pipetted into the pre-treated dialysis membrane and suspended in 15 mL of PBS. The tubes were kept inside a thermostatic shaker (Hybaid Maxi 14) at 37 °C at 100 rpm. At predetermined intervals, 2.5 mL of supernatant was withdrawn and the concentrations of GEF and PTXL were measured using a double beam UV-Vis spectrophotometer. At scheduled time intervals of 0, 2, 6, 24, 46, 58, 72, 86, and 100 h, 2.5 mL of the release media was taken out and the same volume of fresh buffer was replaced. The absorbances of drugs present in the release media was determined using UV-Vis Spectrophotometer and the unknown concentrations were calculated using the OriginPro 9.0 program. The release experiments were conducted in triplicates for the various samples and the results were expressed as mean value ± SD. The results were presented as cumulative drug release percentages (%) against time (hours). The in vitro drug release data were fitted in various kinetic models such as zero order, first order, Krosmeyer-Peppas and Higuchi to determine the appropriate drug release mechanism.

2.3.7. Dissolution Analysis of CSCaCO$_3$NP

The dissolution of CSCaCO$_3$NP were measured by dispensing 60 mg of CSCaCO$_3$NP in 30 mL of with 0.2% ($v/v$) Tween 80 phosphate buffered saline and simulated plasma conditions with pH of 7.4, 6.5 and 5.6. The plasma simulating fluid was prepared by adding 5 g of albumin to 100 mL phosphate buffered saline. These samples were incubated at 37 °C, stirred at 100 rpm in a thermostatic shaker (Hybaid Maxi 14). At designated time, 9 mL of supernatants were collected after ultracentrifugation at 14,000 RPM for 10 min. 9 mL of the respective media was replaced to the tubes. The collected supernatants were predigested by addition of 8 mL of nitric acid and 1 mL of 33% a Hydrogen peroxide and heated at ~160 °C, till the mixture is completely digested and clear. The total calcium contents were measured by atomic absorption spectrometry (Perkin Elmer 900T) at the wavelength of 422.67 nm. The analysis was repeated thrice, and the calcium concentration was expressed as mean ± SD.

2.3.8. Alkalinizing Property of CSCaCO$_3$NP

The alkalinizing profiles of CSCaCO$_3$NP were measured in simulated plasma fluid and phosphate buffered saline with 0.2% ($v/v$) Tween 80. The plasma simulated fluid and Tween 80 buffered PBS were adjusted to three pH of 7.4, 6.5 and 5.6. The alkalinizing property of CSCaCO$_3$NP was measured by dispersing the nanoparticles at three different concentrations of CSCaCO$_3$NP of 5 mg/mL, 1.66 mg/mL, and 0.83 mg/mL in plasma simulated fluid and Tween 80 buffered PBS, respectively. These samples were incubated at 37 °C and stirred at 100 rpm in a thermostatic shaker (Hybaid Maxi 14), and at designated time intervals for 24 h, the pH was measured using the pH meter (LAQUA PH1100). The analysis was repeated thrice, and the pH was expressed as mean ± SD.

3. Results

Physicochemical characterization is required to determine the following characteristics: size, shape, homogeneity, surface area, surface charge, degree of dispersion, drug loading capacity, surface functional groups, and phase of the nanoparticles. These characteristics are essential to determine their biological interaction and kinetics of the nanoparticles in the biological milieu.

3.1. UV-Vis Spectrophotometry, Drug Loading Content and Encapsulation Efficiency

A precise method based on UV-vis spectroscopy for the quantification of GEF and PTXL in a CSCaCO$_3$NP formulation has been developed. GEF and PTXL in a mixture of an equal volume of DMSO and Tween 80 buffer (0.05%) produced a characteristic curve in the UV wavelength range between 200 and 400 nm. The $\lambda_{\text{max}}$ of 332.6 ± 0.2 nm and 247.8 ± 0.3 nm was satisfactory for GEF and PTXL, and for the dual drugs, the $\lambda_{\text{max}}$ of 332.5 ± 0.1 nm for GEF and 248.3 ± 0.8 nm for PTXL was used (Figure A1a). The absorbances of the resulting solutions were measured at 332 and 248 nm for GEF and PTXL (Table A1). For the dual drug
admixture, GEF and PTXL were measured at 332 and 248 nm (Table A2). Drug interaction spectra is shown in Figure A1. The calibration curves plotted with the six points (Figure A1b). The drug interaction between GEF and PTXL at various concentrations is shown in Figure A1c,d. The individual concentration range obeying Beer-lambert law, and the regression characteristics are given in Table A3. The data obtained for analytical performance criteria for this method validation were Linearity (Tables A2 and A3), Recovery and precision (Tables A4 and A5) and sensitivity (Table A5).

For the drug loading, the approach was a simple stirring method for the physical adsorption of drugs, which was facile and efficient. Since GEF and PTXL are hydrophobic drugs, DMSO with Tween 80 buffer (0.05%) was the solvent used for the loading process. The supernatant obtained after centrifugation was examined for the peaks using the UV-Vis Spectrophotometer, and it had remained unchanged compared to the spectra obtained from the pure drugs. The unaltered spectra indicate that no chemical changes have occurred during the loading procedure. No interference arose from the CSCaCO3NP during the measurement of the absorbances of the drug in the supernatant.

The loading content is the capacity of the CSCaCO3NP to load the drugs, the amount of total entrapped drug per total weight of the nanoparticles. The entrapment efficiency is the drug’s ability to be encapsulated efficiently, and it gives the percentage of the drug entrapped successfully. Loading capacity and the entrapment efficiencies of GEF and PTXL in various groups of the mono and dual drug-loaded CSCaCO3NP are given in Figure 2a,b.

**Figure 2.** Loading Content (LC) and Entrapment efficiency (EE): (a) Mono GEF and PTXL in three individual groups of CSCaCO3 nanoparticle formulations; (b) Dual GEF+PTXL in three groups of CSCaCO3 nanoparticle formulations. The error bar is indicated for the corresponding columns, and the mean data are shown above the error bar. LC, loading content; EE, entrapment efficiency; CSCaCO3NP, Blood cockle shell derived CaCO3 nanoparticles; GEF, Gefitinib; PTXL, Paclitaxel; GEF 1-3, groups of GEF loaded CSCaCO3NP; PTXL 1-3, groups of PTXL loaded CSCaCO3NP; GEF 1-3, PTXL 1-3, and GEF1-3-PTXL1-3 are groups of GEF loaded CSCaCO3P, PTXL loaded CSCaCO3NP, and GEF-PTXL loaded CSCaCO3NP.

### 3.2. Field Emission Scanning Electron Microscopy (FESEM), and Energy Dispersion X-ray (EDX) Spectroscopy

The FESEM micrographs of CSCaCO3NP revealed particles with an average size of $63.9 \pm 22.3$ nm (Figure 3). GEF-CSCaCO3NP, PTXL-CSCaCO3NP and GEF-PTXL-CSCaCO3NP exhibited spherical shape and uniform size of $83.9 \pm 28.2$, $78.2 \pm 26.4$, and $87.2 \pm 26.7$ nm, respectively (Figure 3).
Figure 3. FESEM representative images of CSCaCO$_3$NP, GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL-CSCaCO$_3$NP (Scale bar: 100nm) and the corresponding nitrogen adsorption desorption isotherms with its characteristic hysteresis. Plotted with Relative pressure ($P/P_0$) on the x-axis and Amount of Nitrogen adsorbed (cm$^3$/g) on the y-axis.

The elemental composition of CSCaCO$_3$NP, GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, GEF-PTXL-CSCaCO$_3$NP, GEF and PTXL are shown in Table 2. The EDX data show that calcium, carbon, and oxygen are the major elements of the CSCaCO$_3$NP and sodium is present in a very meagre amount. The Ca/C/O are in a molar ratio close 1:1:3 as per the conventional stoichiometrically-derived ratio of CaCO$_3$.

Table 2. Elemental composition of CSCaCO$_3$NP, GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, GEF-PTXL-CSCaCO$_3$NP, GEF and PTXL computed using energy dispersion X-ray (EDX) spectroscopy.

| Samples          | C   | O   | Na  | Ca  | N   | F   | Cl   |
|------------------|-----|-----|-----|-----|-----|-----|------|
| CSCaCO$_3$NP     | 22.44 | 50.09 | 0.21 | 27.26 | ND  | ND  | ND   |
| GEF-CSCaCO$_3$NP | 21.23 | 63.11 | 0.28 | 15.37 | ND  | ND  | ND   |
| PTXL-CSCaCO$_3$NP| 17.53 | 61.41 | 0.30 | 20.76 | ND  | ND  | ND   |
| GEF-PTXL-CSCaCO$_3$NP | 18.53 | 61.65 | 0.30 | 19.53 | ND  | ND  | ND   |
| GEF              | 68.33 | 10.85 | ND  | ND  | 14.02 | 4.53 | 2.28 |
| PTXL             | 83.40 | 16.60 | ND  | ND  | ND  | ND  | ND   |

1 CSCaCO$_3$NP, Blood cockle shell derived CaCO$_3$ nanoparticles; GEF, gefitinib; PTXL, paclitaxel; GEF-CSCaCO$_3$NP, GEF loaded blood cockle shell-derived CaCO$_3$ nanoparticles; PTXL-CSCaCO$_3$NP, PTXL loaded blood cockle shell-derived CaCO$_3$ nanoparticles; GEF-PTXL-CSCaCO$_3$NP, GEF and PTXL loaded blood cockle shell-derived CaCO$_3$ nanoparticles; C, carbon; O, oxygen; Na, sodium; Ca, calcium; N, nitrogen; F, fluorine; Cl, chlorine, and ND, not detected.
3.3. Specific Surface Area and Pore Size

From the nitrogen adsorption and desorption experiments, the resulting isotherm for CSCaCO$_3$NP, GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and the GEF-PTXL-CSCaCO$_3$NP is a Type IV isotherm (Figure 3). The hysteresis loop is formed in all the isotherms. This hysteresis loop shows that the adsorption and desorption curves are almost vertical and parallel, and it belongs to Type 1 and 3. This type of geometry in the isotherm is indicative of mesoporous pore type. The hysteresis loop of CSCaCO$_3$NP begins at ~0.62 P/P$_0$ and ended closer to 1. For the drug loaded nanoparticles, the hysteresis loop began at ~0.82 to ~0.86 and ended very close to the value of 1. GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL-CSCaCO$_3$NP. The surface area of the synthesized CSCaCO$_3$NP, GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL-CSCaCO$_3$NP are 10.7, 8.3, 9.4, and 9.9 (m$^2$/g), respectively. The BJH mean pore width of the CSCaCO$_3$NP, GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL-CSCaCO$_3$NP were 5.2, 5.4, 5.6, and 5.2 (nm), respectively.

3.4. Dynamic Light Scattering

The Zeta ($\zeta$)-potential (mV), hydrodynamic diameters (nm), and PDI of the synthesized CSCaCO$_3$NP, GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP and GEF-PTXL-CSCaCO$_3$NP was obtained (Table 3).

Table 3. DLS results showing the apparent hydrodynamic diameter, polydispersive Index (PDI) and zeta potential.

| Sample          | Hydrodynamic Diameter (nm) | PDI   | $\zeta$-Potential (mV) |
|-----------------|-----------------------------|-------|------------------------|
| CSCaCO$_3$NP    | 179 ± 11                    | 0.3 ± 0.1 | -17.0 ± 1.2          |
| GEF-CSCaCO$_3$NP| 188 ± 5                     | 0.3 ± 0.1 | -21.5 ± 1.3          |
| PTXL-CSCaCO$_3$NP| 268 ± 20                   | 0.3 ± 0.1 | -4.9 ± 3.4           |
| GEF-PTXL-CSCaCO$_3$NP| 274 ± 23               | 0.3 ± 0.1 | -10.3 ± 1.7          |
| GEF             | 149 ± 27                    | 0.2 ± 0.1 | -4.3 ± 1.0           |
| PTXL            | 12 ± 1                      | 0.2 ± 0.1 | -9.5 ± 2.4           |

GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP and GEF-PTXL-CSCaCO$_3$NP were measured in deionized water. GEF and PTXL were measured in PBS with 1% Tween 80 pH 7.4. The data are expressed as mean ± SD.

3.5. Powder X-ray Diffraction

Figure 4a shows the X-ray diffraction patterns obtained for the investigated samples: CSCaCO$_3$NP, GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP and GEF-PTXL-CSCaCO$_3$NP. One can observe that the diffraction peaks of the drugs GEF and PTXL are invariably different from the diffraction peaks obtained from the nanoparticle samples. In the Inorganic Crystal Structure Database (I.C.S.D.), the samples were matched to the ICSD patterns with the highest score: 98-006-2988, 98-010-9087, 98-006-2988, and 98-001-6937 for CSCaCO$_3$NP, GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL-CSCaCO$_3$NP, respectively. The crystal structure obtained from the synthesized CSCaCO$_3$NP (Figure 4b). The lattice parameters are also shown in the same figure. The crystallite size (Å) of CSCaCO$_3$NP, GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL-CSCaCO$_3$NP was 328, 319, 301, and 328, respectively. The diffractograms of GEF and PTXL are shown in Figure A2.
Figure 4. Powder X-ray diffractograms (XRD): (a) XRD patterns of CSCaCO$_3$NP, GEF-PTXL-CSCaCO$_3$NP, GEF-CSCaCO$_3$NP, and PTXL-CSCaCO$_3$NP. Labelled are the miller indices (h, k, l) planes indicating the peaks of the aragonite crystalline phase; (b) Orthorhombic crystalline morphology of the synthesized aragonite CSCaCO$_3$NP along with its lattice parameters.

3.6. Fourier-Transform Infrared Spectroscopy (FTIR)

The FTIR spectra of CSCaCO$_3$NP showed vibrational bands at 1445, 1084, 856, and 714 cm$^{-1}$ (Figure 5). The largest and strongest band appeared at 1445 cm$^{-1}$, and smaller peaks at 1084 and 856 cm$^{-1}$ are attributed to CO$_3^{2-}$ in the CaCO$_3$ molecular structure. The GEF-PTXL-CSCaCO$_3$NP showed new spectral absorption peaks at 952.84 (cyclohexane), 1024.20 (C-F stretch), 2918.30 (C-H stretching) and 3435.22 (aromatic amine and OH$^-$ stretch) (Figure 5). The largest and strongest band exhibited by CSCaCO$_3$NP at 1445 cm$^{-1}$ remained unaltered in the spectra of GEF-PTXL-CSCaCO$_3$NP, GEF-CSCaCO$_3$NP and PTXL-CSCaCO$_3$NP, indicating that the alkyl group is unaffected. The spectral absorption peaks of GEF-CSCaCO$_3$NP displayed less pronounced 1024.20 (C-F stretch) and 952.84 (cyclohexane) cm$^{-1}$ peaks as compared to GEF-PTXL-CSCaCO$_3$NP. The spectral absorption peaks of PTXL-CSCaCO$_3$NP showed a slightly more pronounced 952.84 cm$^{-1}$ (cyclohexane) peak than GEF-PTXL-CSCaCO$_3$NP (Figure 5). The FTIR spectra of GEF and PTXL revealed many absorption peaks corresponding to the chemical groups present in their structures (Figure A3a,b).
Figure 5. Fourier-transform infrared spectroscopy FTIR patterns of CSCaCO$_3$NP (y-axis: 15–100%, corresponding to the lowest point of curve and the highest), GEF-PTXL-CSCaCO$_3$NP (y-axis: 6–100%, corresponding to the lowest point of curve and the highest), GEF-CSCaCO$_3$NP (y-axis: 10–100%, corresponding to the lowest point of curve and the highest), and PTXL-CSCaCO$_3$NP (y-axis: 5–100%, corresponding to the lowest point of curve and the highest). The insert shows the doublet $\nu_4$ the peaks (Pink shaded box), the newly formed peaks are indicated with the grey box (break in x-axis: 1810–2800 cm$^{-1}$).

3.7. In Vitro Drug Release

In vitro release of GEF and PTXL from GEF-CSCaCO$_3$NP, PTXL-CSCaCO$_3$NP, and GEF-PTXL-CSCaCO$_3$NP were studied in PBS containing 0.2% Tween 80 at various pH of 7.4, 6.5 and 5.6 at 37 °C for 100 h. In all the formulations, the release of GEF and PTXL did not exceed more than 30% at 100 h, indicating that the drugs have a slow and sustained release (Figure 6a–e). The data also indicate that the drugs are released at a higher concentration in the moderately acidic pH of 5.6, when compared to the release of the drugs at the pH values of 6.5 and 7.4. The cumulative release of GEF at the end of 100 h was ~16, ~17 and ~19% from GEF-CSCaCO$_3$NP in the pH of 7.4, 6.5 and 5.6, respectively. The cumulative release of PTXL at the end of 100 h was ~18, ~21 and ~22% from PTXL-CSCaCO$_3$NP in the pH of 7.4, 6.5 and 5.6, respectively. The cumulative release of GEF/PTXL at the end of 100 h was ~22/18, ~23/20 and ~26/23% from GEF-PTXL-CSCaCO$_3$NP in the pH of 7.4, 6.5 and 5.6, respectively. The release characteristics could be attributed to the pH dependent solubility of the nanocarrier.
Figure 6. In vitro release of: (a) GEF from GEF-CaCO₃NP in PBS with 0.2% (v/v) Tween 80 at pH of 5.6, 6.5, and 7.4; (b) PTXL from PTXL-CaCO₃NP PBS with 0.2% (v/v) Tween 80 at pH 6.5, 5.6, and 7.4; (c) GEF and PTXL from GEF-PTXL-CaCO₃NP in PBS with 0.2% (v/v) Tween 80 at pH of 7.4; (d) GEF and PTXL from GEF-PTXL-CaCO₃NP in PBS with 0.2% (v/v) Tween 80 at pH of 6.5; (e) GEF and PTXL from GEF-PTXL-CaCO₃NP in PBS with 0.2% (v/v) Tween 80 at pH of 5.6; and (f) Calcium concentrations released from CaCO₃NP in PBS with 0.2% (v/v) Tween 80 and simulated plasma conditions at pH of 5.6, 6.5, and 7.4 (Break in y-axis: 45–69).

The experimental release data for GEF and PTXL in the three formulations were fitted to different kinetic models. The best fitting model with the $R^2$ value (close to 1) obtained for different models (Table 4). The best fitting model was determined by comparing the $R^2$ values. For GEF, the model followed was zero order for all the pH values studied, and the same type of release was determined for PTXL. The release kinetics was different for the release of GEF and PTXL from the dual drug loaded system, but still the overall release model was Zero order. With the Krosmeyer-Peppas model the Fickian release was
observed for GEF and PTXL released from GEF-CSCaCO$_3$NP and PTXL-CSCaCO$_3$NP in the pH of 7.4, 6.5, and 5.6, respectively. Non-Fickian release was observed for GEF and PTXL from the GEF-PTXL-CSCaCO$_3$NP in all the pH of 7.4, 6.5, and 5.6 proving that the concentration of the drug was not affecting the release of the drugs from the dual drug delivery system.

Table 4. Correlation coefficients $R^2$ for GEF, PTXL, and GEF-PTXL derived from various kinetics models and the n value for the Krosmeyer-Peppas model in PBS with 0.2% ($v/v$) Tween 80 at pH of 5.6, 6.5, and 7.4.

| Formulations         | Drug | pH   | Zero Order $R^2$ | First Order $R^2$ | Krosmeyer-Peppas $R^2$ | n     | Higuchi $R^2$ |
|----------------------|------|------|------------------|-------------------|------------------------|-------|---------------|
| GEF-CSCaCO$_3$NP    | GEF  | 7.4  | 0.9933           | 0.9944            | 0.9505                 | 0.42 * | 0.9803        |
|                     |      | 6.5  | 0.9816           | 0.9820            | 0.9360                 | 0.33 * | 0.968         |
|                     |      | 5.6  | 0.9905           | 0.9886            | 0.9616                 | 0.33 * | 0.9894        |
|                     |      | 7.4  | 0.9766           | 0.9576            | 0.9602                 | 0.35 * | 0.9695        |
| PTXL-CSCaCO$_3$NP   | PTXL | 7.4  | 0.9761           | 0.9698            | 0.9727                 | 0.54 * | 0.9680        |
|                     |      | 6.5  | 0.9131           | 0.9012            | 0.8880                 | 0.21 * | 0.9063        |
|                     |      | 5.6  | 0.9122           | 0.8916            | 0.8527                 | 0.19 * | 0.8741        |
|                     |      | 7.4  | 0.9761           | 0.9698            | 0.9727                 | 0.54 * | 0.9680        |
| GEF-PTXL-CSCaCO$_3$NP | GEF  | 7.4  | 0.9761           | 0.9698            | 0.9727                 | 0.54 * | 0.9680        |
|                     |      | 6.5  | 0.9813           | 0.9776            | 0.9802                 | 0.50 * | 0.9758        |
|                     |      | 5.6  | 0.9894           | 0.9832            | 0.9257                 | 0.51 * | 0.9849        |
|                     |      | 7.4  | 0.9846           | 0.9829            | 0.9734                 | 0.56 * | 0.9799        |
|                     | PTXL | 6.5  | 0.9878           | 0.9739            | 0.9860                 | 0.50 * | 0.9722        |
|                     |      | 5.6  | 0.9913           | 0.9891            | 0.9522                 | 0.59 * | 0.9904        |

* Fickian diffusion, * Non-Fickian diffusion.

3.8. Dissolution Analysis of CSCaCO$_3$NP

The dissolution profile of CSCaCO$_3$NP (60 mg) in phosphate buffered saline with 0.2% ($v/v$) Tween 80 and in simulated plasma conditions for a period of 24 h in pH of 7.4, 6.5 and 5.6 were determined. Calcium was released at a higher concentration at the pH of 5.6 and remains the highest, followed by the concentration detected at the pH of 6.5 and 7.4, whereas the dissolution profiles remain highest at the pH of 5.6 in the simulated plasma condition followed by the concentration detected at the pH of 6.5 and 7.4 (Figure 6f).

3.9. Alkalinization Profiles of CSCaCO$_3$NP

The alkalinization capacity of CSCaCO$_3$NP in plasma simulating conditions was determined for 24 h (Figure 7a) and in phosphate buffered saline with 0.2% ($v/v$) Tween 80 (Figure 7b) at pH of 7.4, 6.5, and 5.6 with concentrations of 5.00, 1.66 and 0.83 mg/mL. The neutralization capacity of CSCaCO$_3$NP in plasma simulation conditions at the end of 24 h was highest for the 5 mg/mL at the starting pH of 5.6, reaching up to the pH of 6.6. Less appreciable neutralization was observed at the same concentration at the starting pH of 7.4, reaching up to 7.6. The neutralization capacity of CSCaCO$_3$NP in phosphate buffered saline with 0.2% ($v/v$) Tween 80 at the end of 24 h was highest for the 5 mg/mL at the starting pH of 5.6, reaching up to the pH of 8.4. Appreciable neutralization was observed at the same concentration at the starting pH of 7.4, reaching up to the pH of 8.9.
Figure 7. Alkalinization profiles of CSCaCO$_3$NP: (a) In simulated plasma fluid at pH of 7.4, 6.5 and 5.6 and concentrations of 5.00 mg/mL, 1.66 mg/mL and 0.83 mg/mL (Break in y-axis: 7.12–7.35) and (b) In phosphate buffered saline with 0.2% (v/v) Tween 80 at pH of 7.4, 6.5 and 5.6 and concentrations of 5.00 mg/mL, 1.66 mg/mL and 0.83 mg/mL. Dotted line indicating the pH of 7.4 in both the figures.

4. Discussion

Calcium carbonate nanoparticles have been synthesized by both top-down [35,45,49] and bottom-up methods [50,51]. Each method has its advantages and disadvantages. A critical consideration is that the formulation process must be robust enough to ensure high reproducibility and be streamlined to allow for the ease of scale-up production. Care must be taken that the physicochemical properties of synthesized nanoparticles be preserved throughout the formulation process. Some of the popular methods for synthesizing calcium carbonate nanoparticles viz. precipitation [43], sol-gel method [52,53], and layer by layer deposition [51]. As explained by the name, the top-down method is where larger particles (blood cockle shells) are broken down into smaller nanometer-sized particles. This study involves the usage of both the chemical and the mechanical processes to synthesize the CSCaCO$_3$NP. Researchers have used milling technology to synthesize poorly water-soluble compounds [54]. In the initial stages of the nanoparticle synthesis, Tween 80 was used as the nonionic surfactant to keep the nanoparticles from growing and aggregate during the vigorous stirring step. Kamba et al. [47] and Isa et al. [40] have used Tween 80 to synthesize CSCaCO$_3$NP by the high-pressure homogenization method. In contrast, other researchers have used BS-12 to synthesize the CSCaCO$_3$NP from cockle shells [39,49].

Milling is an acceptable fine particle production method where mechanical energy is applied to the solid material to break the bonding between the atoms or molecules [55]. The mechanical dry milling step becomes essential to break down the particles further. The usage of ceramic balls and the balls constant hitting with the container while milling helps break the particles further. Besides, this method is more effective and less expensive than a high-pressure homogenizer technique [35]. Loading the hydrophobic drug like PTXL and GEF onto CSCaCO$_3$NP involved a simple stirring method and was effective. Since both GEF and PTXL are hydrophobic drugs, DMSO with Tween 80 buffer (0.05%) was used as solvent for drug loading.

The physicochemical characterization: size, PDI, surface chemistry, drug loading and encapsulation, chemical composition and impurities present must be known to determine the stability and the biological effects of the synthesized nanoparticles [55]. GEF has been quantified using UV spectrophotometry [56,57], liquid chromatography-tandem mass spectrophotometry [58], and high-performance liquid chromatography (HPLC)-UV [59]. PTXL has been quantified using UV-Vis spectrophotometry [60], and HPLC [61–63]. Methods
such as simultaneous equation, Q absorbance [64], difference spectrophotometry, and derivative spectrophotometry [65] are available for simultaneous estimation of various drugs [66]. Current UV-Vis spectrophotometry, though old-fashioned, was chosen because it is facile, sensitive, less time-consuming, and cost-effective. To date, there is no literature reported on simultaneous quantification of GEF and PTXL in a nanoparticulate formulation, which is the novelty here. UV-Vis spectrophotometer was used for the measurement of GEF [67–69] and PTXL [70–72] in various other nanoparticles for determining the loading content and/or encapsulation efficiency. The \( \lambda_{\text{max}} \) of 332.6 \( \pm \) 0.2 nm and 247.8 \( \pm \) 0.3 nm was satisfactory for GEF and PTXL and, this \( \lambda_{\text{max}} \) was similar than the wavelength used by other researchers [59,60,63,69]. The developed method was validated and the analytical performance criteria for linearity (Table A3), recovery and precision (Tables A4 and A5) and sensitivity (Table A5) were found to be reliable and meeting the recommendations of the International Conference on Harmonization Q2(R1) guidelines [46].

Drug-loading and drug-entrapment percentages are vital parameters in the synthesis of nanomedicines [73]. In the three formulations GEF1, GEF2 and GEF3, it was found that the loading content was highest when the concentration of nanoparticles was lowest, and it reduced further from 2.8 \( \pm \) 2.6 (\%), 2 \( \pm \) 1 (\%) to 1.5 \( \pm \) 1.1 (\%), respectively when the quantity of nanoparticles was increased. Less drug availability for loading and hence the reduced loading percentage. A similar trend was observed in the three formulations for PTXL, namely, PTXL1, PTXL2 and PTXL3 nanoparticles, where the loading content reduced from 1.4 \( \pm \) 0.9 (\%), 1 \( \pm \) 0.1 (\%) to 0.4 \( \pm \) 0.1 (\%), respectively, when the quantity of nanoparticles was increased. For the dual drug-loaded GEF1-PTXL1, GEF2-PTXL2 and GEF3-PTXL3 group of nanoparticles, a similar trend in the decrease of loading content was observed from 2 \( \pm \) 0.1/0.9 \( \pm \) 0.1 (\%), 1.1 \( \pm \) 0.2/0.5 \( \pm \) 0.1 (\%) to 1.1 \( \pm \) 0.1/0.4 \( \pm \) 0.1 (\%), respectively for GEF/PTXL (Figure 2b).

Interestingly, the loading content of GEF was always higher when compared to the loading content of PTXL, and it is observed when the concentration of drug and CSCaCO\(_3\)NP are kept similar. The loading efficiency of drugs into the nanoparticles is also governed by the surface area available [74] on the nanoparticles. Another critical factor is the water solubility of the drugs employed. The lower loading content of less than 10% is usually observed for inorganic carrier-based nanoparticles [73], concurrent with the current data. Other researchers have obtained lower loading content of 2.4 \( \pm \) 0.3\% to 7.6 \( \pm \) 0.9\% [75] for GEF-loaded PLGA microspheres, 0.3 \( \pm \) 0.1\% for DOX-calzite hybrid crystals [76], and 0.09\% to 0.39\% for human recombinant parathyroid hormone-loaded CSCaCO\(_3\)NP [38].

Besides the above-stated facts, other points to be considered for lower LC are the physical and electrostatic interaction during the drug loading process. The CSCaCO\(_3\)NP is negatively charged and both GEF and PTXL are negatively charged. This negative charge could contribute to electrostatic repulsion leading to lower loading content. Another factor is the concentration of drugs used during the loading process. On the other hand, higher LC is required so that the amount of carrier nanoparticles is reduced. Since we aim to harvest the alkalinizing property of calcium carbonate and GEF and PTXL’s potential benefits in the same system, the lower loading content is accepted for future research. This point also facilitates the prospects of synthesizing CSCaCO\(_3\)NP with higher LC by modifying the synthesis technique of CSCaCO\(_3\)NP, drug loading process, or surface functionalization of nanoparticles.

A fraction of the drug that is incorporated into the nanoparticles relative to the total amount of drug added is defined as entrapment efficiency [77]. The entrapment efficiency for GEF in GEF1, GEF2 and GEF3 nanoparticles was lowest when the concentration of nanoparticles was lower, and it increased further from 47.4 \( \pm \) 20.2 (\%), 52.3 \( \pm \) 18.1 (\%) to 53.4 \( \pm \) 17.6 (\%), respectively when the quantity of CSCaCO\(_3\)NP was increased (Figure 2a). For PTXL in PTXL1, PTXL2 and PTXL3 the entrapment efficiency was 32.1 \( \pm \) 10.8, 36.8 \( \pm \) 3.7, and 20.8 \( \pm \) 1.6, respectively. For the dual drug-loaded GEF1-PTXL1, GEF2-PTXL2 and GEF3-PTXL3, a trend of decrease and then increase of entrapment efficiency was observed.
from 50 ± 2.1/45.6 ± 0.3 (%), 43 ± 8.9/37.5 ± 5.7 (%) to 45 ± 10.3/43.9 ± 7.2 (%), respectively for GEF and PTXL (Figure 2a).

Out of the three formulations, GEF2 is selected since it has a higher entrapment efficiency 52.3 ± 18.1 (%) and higher loading content 2 ± 1 (%) when compared with the other groups. Similarly, PTXL2 is suitable with its highest encapsulation efficiency 36.8 ± 6.5 (%) and higher loading content 1 ± 0.1 (%). On the other hand, GEF1-PTXL1 will be suitable since it possesses higher entrapment efficiency (50 ± 2/45.6 ± 0.3%) and the highest loading content (2 ± 0.1/0.9 ± 0.1%) of GEF and PTXL, respectively. The observed trend in the LC (%) and the entrapment efficiency (%) was similar to that data obtained for a few anti-cancer drugs like doxorubicin [33,34] and docetaxel [37] loaded onto the blood cockle shell derived CaCO$_3$NP. This group of nanoparticles were used for the characterization studies.

The size of nanoparticles is the most crucial parameter to be considered while designing nanomedicines. The size affects the particles behaviour in vivo, viz. internalization into the cells, deposition, and reticuloendothelial clearance. The shape of the nanoparticles also is an important criterion that will define how the drug will behave In vitro and in vivo. Usually, the abiogenic aragonites are rod or needle-shaped, but the biogenic aragonites are sometimes elliptical shapes, as observed by Falini et al. [78]. Another study on the arrangement of cross lamellar layers of molluscan shells indicates that the aragonites form elongated rod-shaped crystals [40]. Islam et al. [79] and Kamba et al. [47] have synthesized rod-shaped cockle shell-derived aragonite calcium carbonate nanoparticles. Electron microscopic studies reveal that the CSCaCO$_3$NP are mostly spherical, which agrees with the findings of other studies involving calcium carbonate nanoparticles [33,49]. Compared to the size of cockle shell-derived CaCO$_3$NP synthesized by Isa et al. (13.94–23.95 nm) [40] and Danmaigoro et al. (24 ± 4.07 nm) [33], the CSCaCO$_3$NP synthesized in this study are larger (63.9 ± 22.3 nm). The spherical shape of the plain and drug-loaded CSCaCO$_3$NP is in coherency with other researchers.

The hydrodynamic diameter of synthesized nanoparticles was greater than the doxorubicin-loaded CSCaCO$_3$NP (185.6 ± 2.4) obtained by Danmaigoro et al. [33] but smaller than oxytetracycline-loaded CSCaCO$_3$NP (276 ± 6.3) [80]. The negative ζ-potential is concurrent with the findings of other researchers [33,80]. According to Bhattacharjee et al., the Zeta potential measures the surface potential of the nanoparticles and not the charge or the charge density. Hence the value of the zeta potential is vital when compared to the negative/positive value associated with the potential. The majority of naturally occurring surfaces and molecules exhibit negative charge, and hence no wonder calcium carbonate exhibits a negative zeta potential. Various other parameters play an important role in the determination of the zeta potential like pH of the solvent, ionic strength, and the concentration of nanoparticles [81]. In contrast, positively charged calcium carbonate nanoparticles were synthesized by Lee et al. where the source of calcium carbonate was ground seashells. The same study gives the striking data of the size measured using SEM and DLS to be ~30 nm and 2187 nm [82], where the size measured with SEM is about 72 times lesser than the size obtained by DLS.

When we examined the hydrodynamic diameters, and the size measured using electron microscopy from past research with cockle shells, we could calculate up to a 17–31% increase in the size measured using DLS when compared to the size measured by electron microscopy [33,34,80]. When we compare the data of the size of the particles from the electron micrographs and hydrodynamic diameter from DLS, it is evident that the latter value is relatively higher, the reason for this discrepancy have been already explained [83]. Hydrodynamic diameter data is based on the intensity of light scattering fluctuations by the particles. In contrast, in TEM, the scattered electrons’ size is measured from the particles under a vacuum. For SEM, the size’s measurement is from the electrons emitted from the nanoparticles under the vacuum. The metal coating carried out during SEM was found to introduce the error rate up to 14 nm [84]. The TEM and SEM gives us the two-dimensional projection image of the nanoparticles. The broad size distribution observed in the hydro-
dynamic diameter of CSCaCO\textsubscript{3}NP and drug-loaded CSCaCO\textsubscript{3}NP can be attributed to various factors such as the aggregation or opsonization of particles in the liquid medium (here, deionized water) \cite{55,85}. GEF and PTXL in PBS with 1% Tween 80 was found to be negatively charged. The PDI is the ratio between mean particle size and standard deviation, and it reflects the homogeneity of the size distribution \cite{82}. Though the PDI obtained for the synthesized particles was ~0.3, we cannot rule out the possibility that there could be a polydisperse population since we follow the top-down method of nanoparticle synthesis.

The EDX data of the CSCaCO\textsubscript{3}NP, revealed that the Ca/C/O was ~1:1:3, indicative of pure calcium carbonate. Hazmi et al. \cite{21} have reported 1.3% of Mg, Na, P, K, and other elements (Fe, Cu, Ni, B, Zn, and Si) in the blood cockle shells of western peninsular Malaysia. Another study reported detection of Al and S peaks in addition to the Ca/C/O \cite{86}. When we analyzed the EDX data of drug-loaded nanoparticles, the ratio of Ca/C/O was not ~1:1:3, and the elemental percentage of calcium was less than that of the CSCaCO\textsubscript{3}NP which suggests the presence of other elements which could be due to the surface functionalization with the drugs. It is interesting to note that when GEF with the molecular formula of C\textsubscript{22}H\textsubscript{24}ClNF\textsubscript{4}O\textsubscript{3} \cite{87} was analyzed, oxygen (10.85%), carbon (68.33%), nitrogen (14.02%), fluorine (4.05%), and chlorine (2.28%) were obtained. For PTXL, with the molecular formula C\textsubscript{47}H\textsubscript{51}NO\textsubscript{14} \cite{88}, only oxygen (16.37%) and carbon (80.63%) were inferred from the spectra, where the N peak could not be observed, even after repeated measurements at different sites.

This XRD result of synthesized nanoparticles show that they are aragonite crystals. The results are in agreement with other researchers where various other drugs like vancomycin \cite{39}, doxorubicin \cite{33}, thymoquinone, and doxorubicin \cite{89} were loaded onto the CSCaCO\textsubscript{3}NP and the aragonite phase remained unaltered. Other researchers have found that the crystallites are arranged in a cross lamellar pattern, as observed in other Mollusca and bivalves belonging to the same Arcidae family \cite{90–92}. Furthermore, this is the cockle shells’ microstructure, broken down by the mechanical milling to a nanometer size. From the paper published by Bragg in 1924, one could say that the aragonite and calcite share the same chemical formula and similar diffraction patterns but vary significantly in their crystalline arrangement \cite{93}. A study in 2019 by Sampath et al. \cite{92} proved the presence of a calcite layer and an aragonite morphology in Anadara inaequivalvis shells. Two studies by Yang et al. \cite{94} and Chong et al. \cite{95} revealed that there occurs a strong peak at 2\theta of 29.4, indicative of calcite, and this peak disappeared when the calcium carbonate became aragonite. In a paper published by Hussein et al. \cite{53} where the cockle shells were used to synthesize nanoparticles using a sol-gel method, this resulted in a calcite phase, characterized by the peak of 2\theta at 29.5, was the confirmatory sign of calcite. In the current study, we found no diffraction around that region in the diffractogram of the nanoparticles synthesized, which indicates that these nanoparticles are purely aragonite. The crystallite size of the synthesized nanoparticles ranged from 30.1 nm to 32.8 nm. In a 2020 study, calcium carbonate nanoparticles of crystallite size of 61.4 nm were synthesized from cockle shells as the source of calcite calcium carbonate nanoparticles \cite{53}. Another study by Lee et al. \cite{82} shows that calcite calcium carbonate nanoparticles were ~30 nm, which is in the same range as the crystallite size obtained in this study.

To investigate the interaction between the CSCaCO\textsubscript{3}NP and the drugs, FTIR was carried out. Spectral analysis provides us with the position, shape, and relative intensities of the vibrational bands. FTIR spectra result from the absorption of electromagnetic radiations at frequencies that correlate to the vibration of a specific set of chemical bonds form within a molecule \cite{96}. It is interesting to note that the chemical bonds formed between the nanomaterials and the drugs are usually hard to interpret following the conventional database of known vibrational frequencies, so it is vital to determine the relationship between the drug and the nanoparticles. The calcium carbonate nanoparticles we have synthesized exhibit the conventional peaks of the carbonate ion (CO\textsubscript{3}\textsuperscript{2−}). The carbonate ions show four significant vibration modes (ν\textsubscript{1} to ν\textsubscript{4}) between 600 and 1500 cm\textsuperscript{-1} \cite{97,98} (ν-stretching). The reported vibrational frequencies of Ca(CO\textsubscript{3}) belonging to aragonite crystalline
symmetry is as follows: 1080 (ν₁), 866 (ν₂), 1504, 1492 (ν₃) and 711, 706 (ν₄) (Table 5) [99]. When we look at the structure and bonds present in a calcium carbonate molecule, there is the ionic bond between the Ca²⁺ and the CO₃²⁻ polyatomic ion. Also, there exists covalent bonding between the non-metallic atoms of carbon and oxygen (CO₃²⁻). Though the cationic coordination in aragonite is nine, the cationic electrostatic forces have a negligible effect on the more strongly bound anions’ internal vibrations. The anion-anion forces play a significant role in bringing about changes in the vibrational frequencies rather than anion-cation forces [100]. The salient point is that using the IR spectra can differentiate between the calcite and the aragonite, as calcite sometimes lacks the ν₁ mode of vibrations and the characteristic vibrational band assignment for aragonite: ν₁ at 1083 cm⁻¹, and ν₄ is a doublet [97] at 714 and 700 cm⁻¹ [99]. The presence of a peak at 858 cm⁻¹ in the spectra of non-biogenic calcium carbonate is a tell-tale sign of the aragonite phase [101]. The ν₂ and the doublet peak confirm crystalline aragonite instead of an amorphous state [102]. The absorption peaks at 710 and 872 cm⁻¹ are always associated with the calcite phase [103]. The result of the PWRD for the CSCaCO₃NP in the current work correspond to the aragonite phase. A 2002 study on the marine mussel Arca brunesi mentioned that the band at 1082 cm⁻¹ is observed only in the aragonite crystalline matrix [98], while on the other hand, the absence of a band around this region has been attributed to calcite. In a study where the researchers synthesized non-biogenic calcium carbonate, a peak at 1089 cm⁻¹ (quite close to 1082 cm⁻¹) was observed in the calcite spectra [95].

| Normal Vibrational Assignments | Current Study | Position (cm⁻¹) |
|--------------------------------|---------------|-----------------|
| ν₁ Symmetric C-O stretching    | 1084          | 1072.29         | NA              | ~1082 |
| ν₂ CO₃ out-of-plane deformation mode | 856          | 854.77          | 851             | 855   |
| ν₃ Asymmetric C-O stretching mode | 1445         | 1452            | 1444.05         | 1455.16 | ~1455 |
| ν₄ OCO (in-plane deformation) bending | 714          | 707.58          | 707             | 708   | ~709  |
| ν₁ + ν₄                         | 1786          | NA              | NA              | NA    | 1786  |

¹ [80], ² [33], ³ [37], ⁴ [47], NA-not available.

The spectral absorption peaks of GEF-CSCaCO₃NP demonstrated less pronounced 3412 cm⁻¹ (N-H/O-H stretch), 1024 (C-F stretch) and 953 cm⁻¹ (alkane/aromatic deformation of C-H group) cm⁻¹ peaks as compared to GEF-PTXL-CSCaCO₃NP. The spectral absorption peaks of PTXL-CSCaCO₃NP demonstrated a slightly more pronounced ν₂ band, 953 cm⁻¹ (cyclohexane/alkane/C-H in-plane deformation) and a weak 1022 cm⁻¹ (C-N stretching) band. The spectral absorption peaks of GEF-PTXL-CSCaCO₃NP demonstrated new vibrational bands at 953 cm⁻¹ (cyclohexane/alkane), broader 1024 cm⁻¹ (C-F/C-N stretch), very weak 2918 cm⁻¹ (CH₃/C-H/alkanes anti-symmetric stretch), and weak 3435 cm⁻¹ (N-H/O-H stretch) (Figure 5) bands [96,104,105]. The largest and strongest band exhibited by CSCaCO₃NP at 1445 cm⁻¹ remained unaltered in the spectra of GEF-PTXL-CSCaCO₃NP, indicating that the alkyl group is unaffected. All these changes indicate that the drugs have successfully bound to the nanoparticles.

Nitrogen adsorption and desorption experiments are usually used to determine the pore characteristics and the nature of adsorbent/adsorbate interactions. When the experiment is carried out at a constant temperature, the amount adsorbed is recorded as the adsorptive pressure or concentration function. The relation between the adsorbed amount of gas and the gas’ equilibrium pressure at a constant temperature is called the adsorption isotherm [106]. The isotherm quality is the first characteristic to be noted when analyzing adsorption data. The isotherms provide valuable data about the pore characteristics and the nature of adsorbent/adsorbate interactions. All the isotherms obtained from the synthesized nanoparticles were Type IV and was classified based on the BET classification system and the International Union of Pure and Applied Chemistry (IUPAC) manual [107].
The BET method has its weakness in the theoretical assumptions. Nevertheless, it is one of the most widely used methods for evaluating porous materials’ surface area and porosity. This type of isotherm is characterized by the “hysteresis loop,” where capillary condensation occurs, with an initial loop formed by the mono-multi layer adsorption, a 2nd loop by the desorption of gases. This type of isotherm indicates that the nanoparticles are mesoporous [108,109]. All the isotherms produced by the nanoparticles show hysteresis at the high-pressure region, indicating the isotherm reliability for data validity. The hysteresis loop was very narrow, with the adsorption and desorption branches being nearly vertical and parallel above 0.8 relative pressure (Figure 3). The hysteresis loop is a mixture of H1 and H3. The two branches are almost vertical and nearly parallel to each other, but they lack the plateau region towards higher relative pressure. We designated both H3 and H1 as H3 type of hysteresis does not have the plateau and resembles the hysteresis loop of the isotherms obtained. Singh and Williams’s paper indicates that H3 cannot be a Type IV due to plateau’s presence in the latter [110]. Type IV was the appropriate type since no other isotherm type coincides with the isotherms obtained in this study. As per the IUPAC recommendation, the materials containing pore widths between 2 nm and 50 nm are classified as mesopores. The BET area of the type IV isotherms is considered “true probe accessible surface area” [109]. Though we have designated the isotherms to be type IV, they lack the plateau towards the higher P/P0.

The nanoparticles have a higher surface area when compared to the size, this being the reason why nanoparticles are a perfect drug delivery system [111]. There are differences in the surface areas and pore width of calcium carbonate nanoparticles, as shown in Table 6. It could be due to the presence of various elemental and polar surface functional groups [106] in drug-loaded CaCO3NP. The classical range for application of BET for type IV isotherm is p/p0 of 0.05–0.3. It is apparent that the surface area and pore width obtained by researchers who used cockle shells [33,37] as the primary source of calcium carbonate remains in a similar range as the result from this study and do not vary significantly. It is interesting to observe that the amorphous calcium carbonate nanoparticles synthesized by Sun et al. [112] have the highest surface area regarding calcium carbonate nanoparticles. However, these researchers have synthesized amorphous calcium carbonate nanoparticles, which cannot be compared to the crystalline counterparts.

### Table 6. Surface area and pore width of various calcium carbonate nanoparticles.

| Materials                                      | Names                        | Surface Area (m²/g) | Pore Width (nm) |
|------------------------------------------------|-----------------------------|---------------------|-----------------|
| Blood cockle shells derived calcium carbonate nanoparticles ¹ | CSCaCO3NP *                 | 10.7                | 5.2             |
|                                                | GEF-CSCaCO3NP *             | 8.3                 | 5.4             |
|                                                | PTXL-CSCaCO3NP *            | 9.4                 | 5.6             |
|                                                | GEF-PTXL-CSCaCO3NP *        | 9.9                 | 5.2             |
| Cockle shells derived CaCO3 NP ²              | CS-CaCO3NP *                | 6.18 ± 0.65         | 4.48            |
|                                                | CaCO3 NP *                  | 6.95                | 7.12            |
|                                                | DTX-CaCO3NP *               | 38.73               | 4.03            |
|                                                | CaCO3 NP (in various solvents) * | 0.96–26          | 1.8–7.58       |
| Calcium carbonate nanoparticles ⁵              | N-Cal *                     | 15.8                | NA              |
| Calcium carbonate nanoparticles ⁶              | Amorphous CaCO3 NP *        | ~350                | 8–9             |

¹ Current study, ² [33], ³ [37], ⁴ [53], ⁵ [82], ⁶ [112], ⁷ Aragonite, ⁸ Calcite, ⁹ Amorphous. CSCaCO3NP, Blood cockle shell derived CaCO3 nanoparticles; GEF-CSCaCO3NP, GEF loaded Blood cockle shell derived CaCO3 nanoparticles; PTXL-CSCaCO3NP, PTXL loaded Blood cockle shell derived CaCO3 nanoparticles; GEF-PTXL-CSCaCO3NP, GEF and PTXL loaded Blood cockle shell derived CaCO3 nanoparticles; DTX-CaCO3NP, Docetaxel loaded cockle shell derived CaCO3 nanoparticles; N-Cal, Nano calcium carbonate; NA, not available.

In vitro drug release studies of GEF and PTXL were carried out in PBS with 0.2% (v/v) Tween 80 at pH 6.5 [32], 5.6 [76,113], and 7.4 at 37 °C by the dialysis method [48]. The drug release data suggests that: (1) the drug will be released from the nanoparticles at a higher concentration inside the cancer cell when compared to the release in the normal physiological pH, and (2) sustained release kinetics of the drugs for a period of 100 h could be achieved, as the physical structure of the calcium carbonate nanoparticles and the pores
facilitate this release behaviour. Therefore, we believe that the drug released from the GEF-PTXL-CSCaCO$_3$NP will facilitate synergistic release of GEF and PTXL in a synergistic manner to achieve the speculated synergistic effects. The lower release data of this study is in concurrence with the release data obtained for paclitaxel in thiol-terminated PEG-paclitaxel-conjugated gold nanoparticles where only 10% release was obtained for a period of 120 h [114]. This is similar to the release observed in the study of Wu et al. [42] where calcium carbonate nanoparticles were loaded with PTXL and doxorubicin hydrochloride. It is thought that the difference in the release is due to the hydrophobic nature of calcium carbonate and the loaded drugs, so in comparison with the pure drugs, permeation of liquid molecules into the nanoparticles and afterwards diffusion of the drugs to the external release medium becomes more difficult. No burst release of drugs was observed due to the chemical nature of GEF and PTXL being hydrophobic.

As per the article by Mircioiu et al. [115] the modeling and prediction of the release kinetics represent higher complexity and involves tremendous understanding of the physico-chemical, physiological, and mathematical aspects of the release kinetics. The in vitro dissolution and release studies are carried out to examine the drug release model of the newly synthesized nano formulations. The effect of dialysis membrane in underestimating the release of drug has been found. The reason why the release kinetics determined using the dialysis method can be misleading compared to sustained release of drug from nanocarriers is that the drug though is dissolved into the dialysis compartment, but the apparent drug release remains slow due to the slow drug permeation from the dialysis compartment to the external solvent compartment [116]. According to Ma-Ham et al. [117] the dialysis rate of the drugs is determined by the molecular size of the drugs, pore size of the dialysis membrane, solubility of the drugs. The flow rate is faster if the drugs are smaller, hydrophilic, and the dialysis membrane has a larger pore size. In the current study, the dialysis membrane of 14,000 MWCO was used, which has adequate pore size for the entry of the solubilized drugs GEF (446.9) and PTXL (853.9) [88] with the molecular weight much lower than the pores. However, we noticed that the release of the drug was slow and consistent.

The alkalinization or neutralization ability of CSCaCO$_3$NP studied in plasma simulating conditions prove that the highest alkalinization occurs at the lower pH of 5.6 when compared to the pH of 7.4, whereas in phosphate buffered saline with 0.2% (v/v) Tween 80 the alkalinization ability was found to be higher than the physiological pH of 7.4. Som et al. [19] have suggested that CaCO$_3$ nanoparticles increase the pH to about 7.4, which is the physiological pH and did not bring about metabolic alkalosis in the surrounding healthy tissue. The buffering capacity observed in the plasma simulating condition at various pH confirms the speculation that the CSCaCO$_3$NP will help in alkalinizing the tumor microenvironment and hence reduce the incidence of metastasis and tumor growth. The dissolution profile of CSCaCO$_3$NP (60 mg) in phosphate buffered saline with 0.2% (v/v) Tween 80 and in simulated plasma conditions revealed that the dissolution was the highest in the pH of 5.6 and in the plasma simulating condition, when compared to the concentration detected in the 0.2% Tween 80 PBS of the same pH. Calcium was released at a higher concentration in the pH of 5.6 and remains the highest, followed by the concentration detected in 6.5 and 7.4. In a study by Pingitore et al. [118] calcium carbonate in the form of calcite and aragonite were tested for their solubility in various solvents including deionized water. They found that coarsely grained aragonite and calcite phases of non-biogenic calcium carbonate dissolved in deionized water and 15–20 ppm of calcium ions was released in 200 h from 0.1 g of sample of calcium carbonate. The dissolution of CaCO$_3$ follows the basic rate equation with the formation of calcium ions and carbonate ions. In the previous studies, it has been shown that the CaCO$_3$ nanoparticles consistently are soluble in mildly acidic media and served as a buffering agent. The cellular influences of calcium carbonate will be from the calcium ion released and the drug released when they are dissolved in the extracellular or intracellular milieu. Other studies indicate that the calcium carbonate nanoparticles enter the cell by energy-dependent endocytosis [119].
Since calcium functions as an intracellular signal transducer, the release of calcium from the CSCaCO$_3$NP could disrupt cellular signaling and hence resulting in cellular changes: induction of ROS, increase in CHOP, caspase-3 activity, and ER stress. Calcium is deemed to be least toxic among its many metal allies like Zn$^{2+}$, Ni$^{2+}$, and Cu$^{2+}$ as calcium is an essential element for humans and there already exists a regulation system for the metabolism of calcium [120]. The synthesized CSCaCO$_3$NP have attractive characteristics such as higher solubility in mildly acidic pH, drug loading capacity, aragonite crystalline phase which will make scientists choose CSCaCO$_3$NP when compared to other metal-based nanoparticles for designing drug delivery systems. Moving on to the drugs, as GEF and PTXL loaded onto CSCaCO$_3$NP will be released in the tumor site due to the pH-dependent solubility of calcium carbonate nanoparticles. In a study where doxorubicin hydrochloride and PTXL were co-encapsulated in an inorganic/organic hybrid alginate/CaCO$_3$ nanoparticles, dual drug-loaded nanoparticles exhibited significant enhanced cell uptake and nuclear localization compared with the single drug-loaded nanoparticles [42]. Hence, embracing the possibility of synthesizing calcium carbonate nanoparticles with their distinguishing characteristic features and loading them with GEF and PTXL would be the first step in formulating nanomedicines, as a targeted therapy against breast cancer.

5. Conclusions

We have developed a facile, scalable method without using harsh chemicals to produce CSCaCO$_3$NP from the waste shells of blood cockles. Dry ball milling effectively results in nanoparticles of suitable size, morphology, and crystalline phase. We have demonstrated that we could load GEF and PTXL resulting in GEF-CSCaCO$_3$NP and PTXL-CSCaCO$_3$NP. For the first time, we have simultaneously loaded GEF and PTXL to CSCaCO$_3$NP produce dual drug-loaded GEF-PTXL-CSCaCO$_3$NP. We have successfully characterized the synthesized nanoparticles, which reveals that they are spherical, porous, and possess a large surface area compared to the particle size. The FTIR shows that the drugs are bound to CSCaCO$_3$NP. The drug loaded CSCaCO$_3$NP have prolonged release and the CSCaCO$_3$NP show highest solubility in moderately acidic pH solution with alkalization properties in the plasma simulating condition. Though several drug-loaded CSCaCO$_3$NP have been synthesized, dual-drug loaded GEF-PTXL-CSCaCO$_3$NP should have a place in cancer research and treatment due to the potential they possess.

Author Contributions: Conceptualization, S.C., and M.Z.A.B.; data curation, S.C.; writing—original draft preparation, S.C.; writing—review and editing, S.C., N.A.A.R., A.R.I.-S., L.M.Y., C.A.C.A., M.A., N.S.K.G., and M.Z.A.B.; visualization, S.C.; supervision, M.Z.A.B.; project administration, M.Z.A.B.; funding acquisition, A.R.I.-S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the MINISTRY OF HIGHER EDUCATION MALAYSIA, grant number “04-01-19-2097FR” under the Fundamental Research Grant Scheme (FRGS/1/2019/SKK15/ UPM/02/4).

Data Availability Statement: All data generated or analyzed during this research are included in this published article (and its Appendix A) in the form of figures or tables. The datasets generated during and/or analyzed in this current study are available from the corresponding author on a reasonable request.

Acknowledgments: The contribution of this work was supported by the MINISTRY OF HIGHER EDUCATION MALAYSIA, under the Fundamental Research Grant Scheme (FRGS/1/2019/SKK15/ UPM/02/4). The views and opinion presented by the authors do not reflect those of the Fundamental research grant scheme under the Government of Malaysia.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Appendix A

Appendix A.1. Drug Interaction Studies

For the dual drug, 2.5–20 µg/mL for GEF and 1.25–10 µg/mL for PTXL were prepared separately from the stock solution. They were admixed and then the absorbance values were measured at 248 nm and 332 nm for PTXL and GEF. The drug interactions were studied by keeping the concentration of one drug constant while increasing the concentration of the other drug (Figure A1c,d).

Figure A1. UV-Vis spectrophotometric studies (a) UV-vis absorption spectra of GEF, PTXL and DUAL (GEF + PTXL) with its significant peaks (λmax) in an equal admixture of DMSO and 0.05% (v/v) Tween 80; (b) Calibration curve of GEF, PTXL, dual-GEF and dual-PTXL in an equal admixture of DMSO and 0.05% (v/v) Tween 80, with concentration (µg/mL) in the x-axis and absorbance (Arb. unit) in the y-axis. (c) Spectra generated with GEF at a constant concentration and increasing concentrations of PTXL, indicating rise in both the peaks at 248 nm and 332 nm; (d) Spectra generated with PTXL at a constant concentration and increasing concentrations of GEF, indicating rise in the peak assigned to PTXL at 248 nm.
Table A1. Absorbance and inter-day absorbances of GEF and PTXL at various concentrations. Absorbances are expressed as mean ± SD.

| Concentration (µg/mL) | GEF       | PTXL      | GEF       | PTXL      |
|------------------------|-----------|-----------|-----------|-----------|
|                        | Absorbance (λ_max = 332 nm) | Inter-day Absorbance (λ_max = 332 nm) | Concentration (µg/mL) | Absorbance (λ_max = 248 nm) | Inter-day Absorbance (λ_max = 248 nm) |
| 1.25                   | 0.06 ± 0.00 | 0.07 ± 0.01 | 10.00     | 0.13 ± 0.03 | 0.11 ± 0.04 |
| 2.50                   | 0.10 ± 0.02 | 0.11 ± 0.02 | 20.00     | 0.23 ± 0.07 | 0.23 ± 0.08 |
| 5.00                   | 0.19 ± 0.01 | 0.19 ± 0.01 | 30.00     | 0.34 ± 0.06 | 0.38 ± 0.09 |
| 10.00                  | 0.37 ± 0.04 | 0.36 ± 0.04 | 50.00     | 0.55 ± 0.05 | 0.54 ± 0.08 |
| 15.00                  | 0.58 ± 0.00 | 0.58 ± 0.01 | 70.00     | 0.75 ± 0.05 | 0.72 ± 0.07 |
| 20.00                  | 0.76 ± 0.01 | 0.76 ± 0.01 | 90.00     | 0.92 ± 0.03 | 0.90 ± 0.06 |
| 25.00                  | 0.95 ± 0.02 | 0.95 ± 0.02 | -         | -          | -          |

Table A2. Absorbances and inter-day absorbances for simultaneous estimation of GEF and PTXL at various concentrations. Absorbances are expressed as mean ± SD.

| Concentration (µg/mL) | GEF       | PTXL      | GEF       | PTXL      |
|------------------------|-----------|-----------|-----------|-----------|
|                        | Absorbance (λ_max = 332 nm) | Inter-day Absorbance (λ_max = 332 nm) | Concentration (µg/mL) | Absorbance (λ_max = 248 nm) | Inter-day Absorbance (λ_max = 248 nm) |
| 2.50                   | 0.10 ± 0.01 | 0.10 ± 0.01 | 1.25      | 0.18 ± 0.03 | 0.18 ± 0.04 |
| 5.00                   | 0.21 ± 0.01 | 0.21 ± 0.01 | 2.50      | 0.36 ± 0.03 | 0.35 ± 0.03 |
| 7.50                   | 0.31 ± 0.01 | 0.32 ± 0.03 | 3.75      | 0.55 ± 0.05 | 0.57 ± 0.05 |
| 10.00                  | 0.37 ± 0.04 | 0.38 ± 0.04 | 5.00      | 0.66 ± 0.05 | 0.67 ± 0.03 |
| 12.50                  | 0.50 ± 0.01 | 0.49 ± 0.01 | 6.25      | 0.88 ± 0.03 | 0.87 ± 0.03 |
| 15.00                  | 0.58 ± 0.01 | 0.58 ± 0.01 | 7.50      | 1.04 ± 0.03 | 1.03 ± 0.02 |
| 20.00                  | 0.77 ± 0.04 | 0.77 ± 0.04 | 10.00     | 1.35 ± 0.06 | 1.35 ± 0.02 |

Appendix A.2. Linearity

Six-point calibration curves were produced (Figure A1b), and linearity was evaluated by the least square regression method. The data is shown in Table A3.

Table A3. Regression characteristics of GEF and PTXL.

| Parameters               | GEF       | PTXL      | DUAL GEF | DUAL PTXL |
|--------------------------|-----------|-----------|----------|-----------|
| λ_max (nm)               | 332       | 248       | 332      | 248       |
| Beer’s law range (µg/mL) | 2.5–25    | 10–90     | 2.5–20   | 1.25–10   |
| Regression Equation (y = mx +b) | 0.038x + 0.0055 | 0.015x + 0.035 | 0.0379x + 0.0157 | 0.1337x + 0.0301 |
| Regression coefficient (r²) | 0.9995 | 0.9988 | 0.9992 | 0.9988 |
| Recovery (%)             | 100.4 ± 0.6 | 100.3 ± 2.4 | 98.6 ± 5.2 | 101.2 ± 2.0 |

Appendix A.3. Precision and Accuracy

The precision and accuracy were determined using the standard quality control samples prepared in triplicates at different concentration levels covering the entire linearity range. Accuracy value provides the agreeableness between the value which is accepted either as a conventional true concentration and the found concentration. Accuracy is measured in terms of recovery. Recovery study is performed by the addition of a known amount of drug and the assay concentration was calculated. Precision is defined as the degree of repeatability of an analytical method under normal laboratory and operational conditions. The precision of the assay was determined by repeatability (intra-day), the results are provided as RSD (%) for a significant number of replicate measurements. Inter-day precision was determined by analyzing three concentrations of the drugs after a 24-h
interval and precision is expressed in terms of the Relative standard deviation/Coefficient of variation. Accuracy is the percentage of drugs recovered by utilizing the assay from a known added amount. The values from three determinations over three concentration levels were determined. The data is shown in Tables A4 and A5. The following formulae were used to calculate the recovery (Accuracy %) and found concentration:

\[
\text{Recovery (Accuracy %)} = \left( \frac{\text{Found concentration}}{\text{Actual concentration}} \right) \times 100 \quad (A1)
\]

\[
\text{Found Concentration (µg)} = \left( \frac{\text{Absorbance-Intercept}}{\text{Slope}} \right) \quad (A2)
\]

**Appendix A.4. Sensitivity, LOD and LOQ**

Sensitivity was estimated using the limit of detection (LOD) and limit of quantification (LOQ). The limit of detection (LOD) is the lowest concentration of a compound that an analytical process can differentiate from background values. The limit of quantification (LOQ) is the lowest concentration of the standard curve that can be measured with acceptable accuracy, precision, and variability. The data is shown in Table A5. The following formulae were used to calculate LOQ and LOD.

\[
\text{LOD} = 3.3 \left( \frac{\sigma}{S} \right), \quad (A3)
\]

\[
\text{LOQ} = 10 \left( \frac{\sigma}{S} \right), \quad (A4)
\]

where, \( \sigma \) = the standard deviation of the intercept, \( S \) = the slope of the calibration curve.

**Table A4.** Recovery values of GEF, PTXL, dual-GEF, and dual-PTXL.

| Drug          | Actual Concentration (µg/mL) | Found Concentration (µg/mL) | Recovery (%) | RSD (%) |
|---------------|------------------------------|-----------------------------|--------------|---------|
| GEF           | 10.00                        | 10.14                       | 101.5        | 1.4     |
|               | 15.00                        | 15.05                       | 100.6        | 0.6     |
|               | 20.00                        | 19.88                       | 99.4         | 1.3     |
| PTXL          | 10.00                        | 10.13                       | 101.3        | 1.0     |
|               | 20.00                        | 20.53                       | 102.7        | 0.5     |
|               | 30.00                        | 30.93                       | 103.1        | 1.2     |
| Dual GEF      | 7.50                         | 7.60                        | 101.4        | 0.7     |
|               | 12.50                        | 12.71                       | 100.7        | 1.0     |
|               | 15.00                        | 15.11                       | 100.7        | 1.0     |
|               | 3.75                         | 3.90                        | 104.4        | 0.4     |
| Dual PTXL     | 2.50                         | 2.55                        | 102.2        | 1.0     |
|               | 7.50                         | 7.60                        | 102.2        | 2.0     |

**Table A5.** Inter-day precision values, limit of detection (LOD) and limit of quantification (LOQ) of GEF, PTXL, dual-GEF, and dual-PTXL.

| Drug          | Concentration Added (µg/mL) | Found Concentration (µg/mL) | RSD (%) | LOD (µg/mL) | LOQ (µg/mL) |
|---------------|-----------------------------|-----------------------------|---------|--------------|--------------|
| GEF           | 10.00                        | 10.04 ± 0.1                | 0.7     | 1            | 3            |
|               | 15.00                        | 15.14 ± 0.1                | 0.3     |              |              |
|               | 20.00                        | 19.82 ± 0.2                | 1.1     |              |              |
| PTXL          | 20.00                        | 22.66 ± 0.4                | 1.8     | 6.9          | 20.8         |
|               | 90.00                        | 83.06 ± 0.2                | 0.2     |              |              |
|               | 110.00                       | 104.43 ± 1                 | 1.0     |              |              |
| Dual GEF      | 5.00                         | 5.04 ± 0.1                 | 1.6     | 1.7          | 4.2          |
|               | 12.50                        | 12.52 ± 0.1                | 0.9     |              |              |
|               | 15.00                        | 15.12 ± 0.1                | 0.8     |              |              |
|               | 3.75                         | 3.96 ± 0.1                 | 1.9     |              |              |
| Dual PTXL     | 6.25                         | 6.16 ± 0.1                 | 1.3     | 0.8          | 2.3          |
|               | 7.50                         | 7.53 ± 0.1                 | 0.6     |              |              |
Figure A2. Powder X-ray diffractograms (XRD) pattern of GEF and PTXL with the miller indices (h, k, l) planes.

Figure A3. Cont.
Figure A3. Fourier-transform infrared spectroscopy (FTIR) patterns: (a) FT-IR pattern of GEF with labelled peaks corresponding to the functional groups present in its chemical structure (break in x-axis: 2100–2800 cm$^{-1}$); (b) FT-IR pattern of PTXL with labelled peaks corresponding to the functional groups present in its chemical structure (break in x-axis: 1900–2900 cm$^{-1}$).

References
1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 2018, 68, 394–424. [CrossRef]
2. WHO Breast Cancer: Globocan 2020. Available online: https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf (accessed on 10 February 2021).
3. Liao, W.-S.; Ho, Y.; Lin, Y.-W.; Naveen Raj, E.; Liu, K.-K.; Chen, C.; Zhou, X.-Z.; Lu, K.-P.; Chao, J.-I. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Acta Biomater. 2019, 86, 395–405. [CrossRef] [PubMed]
4. Klijn, J.G.M.; Berns, P.M.J.J.; Schmitz, P.I.M.; Foekens, J.A. The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients*. Endocr. Rev. 1992, 13, 3–17. [CrossRef] [PubMed]
5. Slamon, D.; Godolphin, W.; Jones, L.; Holt, J.; Wong, S.; Keith, D.; Levin, W.; Stuart, S.; Udove, J.; Ullrich, A.; et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707–712. [CrossRef] [PubMed]
6. Barker, A.J.; Gibson, K.H.; Grundy, W.; Jones, L.; Holt, J.; Wong, S.; Keith, D.; Levin, W.; Stuart, S.; Udove, J.; Ullrich, A.; et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707–712. [CrossRef] [PubMed]
7. Ward, W.H.J.; Cook, P.N.; Slater, A.M.; Davies, D.H.; Holdgate, G.A.; Green, L.R. Epidermal growth factor receptor tyrosine kinase. Biochem. Pharmacol. 1994, 48, 659–666. [CrossRef]
8. Ranson, M.; Mansoor, W.; Jayson, G. ZD1839 (IRESSA™): A selective EGFR-TK inhibitor. Expert Rev. Anticancer Ther. 2002, 2, 161–168. [CrossRef] [PubMed]
9. Albane, J.; Rojo, F.; Baselga, J. Pharmacodynamic studies with the epidermal growth factor tyrosine kinase inhibitor ZD1839. Semin. Oncol. 2001, 28, 56–66. [CrossRef]
10. Yarden, Y.; Baselga, J.; Miles, D. Molecular approach to breast cancer treatment. Semin. Oncol. 2004, 31, 6–13. [CrossRef]
11. Blanco, E.; Shen, H.; Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 2015, 33, 941–951. [CrossRef]
12. Danhier, F.; Feron, O.; Prétat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148, 135–146. [CrossRef]
13. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6387–6392. [PubMed]
14. Ibiyeye, K.M.; Nordin, N.; Ajat, M.; Zuki, A.B.Z. Ultrastructural changes and antitumor effects of Doxorubicin/Thymoquine-Loaded CaCO$_3$ nanoparticles on breast cancer cell line. Front. Oncol. 2019, 9, 599. [CrossRef]
15. Kamba, A.; Ismail, M.; Ibrahim, T.; Zakaria, Z. Biocompatibility of bio based calcium carbonate nanocrystals aragonite polymorph on NIH 3T3 fibroblast cell line. Afr. J. Tradit. Complement. Altern. Med. 2014, 11, 31. [CrossRef] [PubMed]
16. Jaji, A.Z.; Zakaria, Z.A.B.; Mahmud, R.; Loqman, M.Y.; Hezmeem, M.N.M.; Abba, Y.; Isa, T.; Mahmood, S.K. Safety assessments of subcutaneous doses of aragonite calcium carbonate nanocrystals in rats. J. Nanopart. Res. 2017, 19, 175. [CrossRef]
17. Maleki Dizaj, S.; Barzegar-Jalali, M.; Zarrintan, M.H.; Adibkia, K.; Lotfiour, F. Calcium carbonate nanoparticles as cancer drug delivery system. Expert Opin. Drug Deliv. 2015, 12, 1649–1660. [CrossRef]
18. Islam, K.N.; Bakar, M.Z.B.A.; Noordin, M.M.; Hussein, M.Z.B.; Rahman, N.S.B.A.; Ali, M.E. Characterisation of calcium carbonate and its polymorphs from cockle shells (Anadara granosa). Powder Technol. 2011, 213, 188–191. [CrossRef]
19. Som, A.; Raliya, R.; Tian, L.; Akers, W.; Ippolito, J.E.; Singamaneni, S.; Biswas, P.; Achilefu, S. Monodispersed calcium carbonate nanoparticles modulate local pHi and inhibit tumor growth in vivo. Nano尺度 2016, 8, 12639–12647. [CrossRef] [PubMed]
20. Mohamed, M.; Yousuf, S.; Maitra, S. Decomposition study of calcium carbonate in cockle shell. J. Eng. Sci. Technol. 2012, 7, 1–10.
21. Awang, J.A.; Zakaria, M.Z.A.B.; Mohamed Mustapha, N.; Abu, J.; Yusof, N. Mineral composition of the Cockle (Anadara granosa) shells of West coast of Peninsular Malaysia and it’s potential as biomaterial for use in bone repair. Artic. J. Anim. Vet. Adv. 2007, 5, 591–594.
22. Bharatham, H.; Zakaria, M.Z.A.B.; Perimal, E.K.; Yusof, L.M.; Hamid, M. Mineral and physiochemical evaluation of Cockle shell (Anadara granosa) and other selected Molluscan shell as potential biomaterials. Sains Malais. 2014, 43, 1023–1029.
23. Addadi, L.; Raz, S.; Weiner, S. Taking advantage of disorder: Amorphous calcium carbonate and its roles in biomineralization. Adv. Mater. 2003, 15, 959–970. [CrossRef]
24. Bello Bugallo, P.M.; Cristóbal Andrade, L.; Magán Iglesias, A.; Torres López, R. Integrated environmental permit through Best Available Techniques: Evaluation of the fish and seafood canning industry. J. Clean. Prod. 2013, 47, 253–264. [CrossRef]
25. Kwon, Y.T.; Lee, C.W.; Yun, J.H. Development of vermicast from sludge and powdered oyster shell. J. Clean. Prod. 2009, 17, 708–711. [CrossRef]
26. Seco, N.; Fernández-Sanjurjo, M.J.; Núñez-Delgado, A.; Alvarez, E. Spreading of mixtures including wastes from the mussel shell treatment industry on an acid soil: Effects on the dissolved aluminum species and on pasture production. J. Clean. Prod. 2014, 70, 154–163. [CrossRef]
27. Herbst, R.S. Review of epidermal growth factor receptor therapy. Int. J. Radiat. Oncol. 2004, 59, S21–S26. [CrossRef]
28. Bulusu, K.C.; Guha, R.; Mason, D.J.; Lewis, R.P.I.; Muratov, E.; Kalantar Motamedi, Y.; Cokol, M.; Bender, A. Modelling of compound combination effects and applications to efficacy and toxicity: State-of-the-art, challenges and perspectives. Drug Discov. Today 2016, 21, 225–238. [CrossRef]
29. Jia, J.; Zhu, F.; Ma, X.; Cao, Z.W.; Li, Y.X.; Chen, Y.Z. Mechanisms of drug combinations: Interaction and network perspectives. Nat. Rev. Drug Discov. 2009, 8, 111–128. [CrossRef]
30. Takabatake, D.; Fujita, T.; Shien, T.; Kawasaki, K.; Taira, N.; Yoshitomi, S.; Ishibe, Y.; Ogasawara, Y.; Doihara, H. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231). Int. J. Cancer Res. 2013, 253–264. [CrossRef]
31. Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Pomatico, G.; De Placido, S.; Bianco, A.R.; Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor 1. Clin. Cancer Res. 2000, 6, 2053–2061. [PubMed]
32. Estrella, V.; Chen, T.; Lloyd, M.; Wojtkowiak, J.; Cornnell, H.H.; Ibrahim-Hashim, A.; Bailey, K.; Balagurunathan, Y.; Rothenberg, J.M.; Sloane, B.F.; et al. Acidility generated by the tumor microenvironment drives local invasion. Cancer Res. 2013, 73, 1524–1535. [CrossRef]
33. Danmaigoro, A.; Selvarajah, G.T.; Noor, M.H.M.; Mahmud, R.; Zakaria, Z.A.B. Development of Cockshell (Anadara granosa) derived CaCO₃ nanoparticles for Doxorubicin delivery. J. Comput. Theor. Nanosci. 2017, 14, 5074–5086. [CrossRef]
34. Hamidu, A.; Zakiy, S.; Mansor, R.; Adikia, K.; Lotfiour, F. Calcium carbonate nanoparticles modulate local pHi and inhibit tumor growth in vivo. Nano尺度 2016, 8, 12639–12647. [CrossRef] [PubMed]
35. Kamba, A.S.; Ismail, M.; Tengku Ibrahim, T.A.; Zakaria, Z.A.B. A pH-sensitive, biobased Calcium carbonate aragonite nanocrystal as a novel anticancer delivery system. Biomed. Res. Int. 2013, 2013, 587451. [CrossRef]
36. Ueno, Y.; Futagawa, H.; Takagi, Y.; Ueno, A.; Mizushima, Y. Drug-incorporating calcium carbonate nanoparticles for a new delivery system. J. Control. Release 2005, 103, 93–98. [CrossRef]
37. Hammidi, N.I.; Abba, Y.; Hezmeem, M.N.M.; Razak, I.S.A.; Jaji, A.Z.; Isa, T.; Mahmood, S.K.; Zakaria, M.Z.A.B. Formulation of a sustained release Docetaxel loaded Cockle shell-derived Calcium Carbonate nanoparticles against Breast cancer. Pharm. Res. 2017, 34, 1193–1203. [CrossRef] [PubMed]
38. Jaji, A.Z.; Zakaria, Z.; Mahmud, R.; Loqman, M.Y.; Hezmeem, M.N.M.; Isa, T.; Weni, F.; Hammidi, N.I. Synthesis, characterization, and cytocompatibility of potential cockle shell aragonite nanocrystals for osteoporosis therapy and hormonal delivery. Nanotechnol. Sci. Appl. 2017, 10, 23–33. [CrossRef] [PubMed]
39. Saidykhan, L.; Rukayadi, Y.; Umars, A.; Yazed, L.S.; Abu Bakar, M.Z. Bin Development of nanosized delivery system using cockle shell-derived aragonite nanoparticles for treatment of osteomyelitis. Int. J. Nanomed. 2016, 11, 661. [CrossRef]
40. Isa, T.; Zakaria, Z.; Rukayadi, Y.; Mohb Hezmeem, M.; Jaji, A.; Zakiy, S.; Hammidi, N.; Mahmood, S. Antibacterial activity of Ciprofloxacin-encapsulated Cockle shells calcium carbonate (aragonite) nanoparticles and its biocompatibility in Macrophage J774A.1. Int. J. Mol. Sci. 2016, 17, 713. [CrossRef]
41. Chen, S.; Li, F.; Zhuo, R.-X.; Cheng, S.-X. Efficient non-viral gene delivery mediated by nanostructured calcium carbonate in solution-based transfection and solid-phase transfection. *Mol. Biosyst.* **2011**, *7*, 2841. [CrossRef] [PubMed]

42. Wu, J.-L.; Wang, C.-Q.; Zhuo, R.-X.; Cheng, S.-X. Multi-drug delivery system based on alginate/calcium carbonate hybrid nanoparticles for combination chemotherapy. *Colloids Surf. B Biointerfaces* **2014**, *123*, 498–505. [CrossRef]

43. Liang, P.; Zhao, D.; Wang, C.-Q.; Zong, J.-Y.; Zhuo, R.-X.; Cheng, S.-X. Facile preparation of heparin/CaCO3/CaP hybrid nano-carriers with controllable size for anticancer drug delivery. *Colloids Surf. B Biointerfaces* **2013**, *102*, 783–788. [CrossRef]

44. Bobo, D.; Robinson, K.J.; Islam, J.; Thurecht, K.; Corrie, S.R. Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. *Pharm. Res.* **2016**, *33*, 2373–2387. [CrossRef]

45. Islam, K.N.; Ali, M.E.; Bakar, M.Z.B.A.; Lqman, M.Y.; Islam, A.; Islam, M.S.; Rahman, M.M.; Ullah, M. A novel catalytic method for the synthesis of spherical aragonite nanoparticles from Cockle shells. *Powder Technol.* **2013**, *246*, 434–440. [CrossRef]

46. European Medicines Agency. *ICH Topic Q2 (R1) Validation of Analytical Procedures: Text and Methodology*. European Medicines Agency: London, UK; 2006; pp. 1–15.

47. Kamba, S.A.; Ismail, M.; Tengku Ibrahim, T.A.; Zakaria, Z.A.B. Synthesis and characterisation of calcium carbonate aragonite microcrystals from Cockle shell powder (*Anadara granosa*). *J. Nanomater.* **2013**, *2013*, 398357. [CrossRef]

48. Abouelmagd, S.A.; Sun, B.; Chang, A.C.; Ku, Y.J.; Yeo, Y. Release kinetics study of poorly water-soluble drugs from nanoparticles: Are we doing it right? *Mol. Pharm.* **2015**, *12*, 997–1003. [CrossRef]

49. Mohd Abd Ghafar, S.L.; Hussein, M.Z.; Abu Bakar Zakaria, Z. Synthesis and characterization of Cockle shell-based Calcium carbonate polymorph nanoparticles with surface functionalization. *J. Nanopart. 2017*, *2017*, 8196172. [CrossRef]

50. Som, A.; Raliya, R.; Paranandi, K.; High, R.A.; Reed, N.; Beeman, S.C.; Brandenburg, M.; Sudlow, G.; Prior, J.L.; Akers, W.; et al. Calcium carbonate nanoparticles stimulate tumor metabolic reprogramming and modulate tumor metastasis. *Nanomedicine* **2019**, *14*, 169–182. [CrossRef] [PubMed]

51. Peng, C.; Zhao, Q.; Gao, C. Sustained delivery of doxorubicin by porous CaCO3 and chitosan/alginate multilayers-coated CaCO3 microparticles. *Colloids Surf. A Physicochem. Eng. Asp.* **2010**, *353*, 132–139. [CrossRef]

52. Lauth, V.; Maas, M.; Rezwan, K. An evaluation of colloidal and crystalline properties of CaCO3 nanoparticles for biological applications. *Mater. Sci. Eng. C* **2017**, *78*, 305–314. [CrossRef]

53. Hussein, A.I.; Ab-Ghani, Z.; Che Mat, A.N.; Ab Ghanı, N.A.; Huseın, A.; Ab Rahman, I. Synthesis and characterization of spherical Calcium carbonate nanoparticles derived from Cockle shells. *Appl. Sci. 2020*, *10*, 7170. [CrossRef]

54. Chen, H.; Kemtong, C.; Yang, X.; Chang, X.; Gao, J. Nanonization strategies for poorly water-soluble drugs. *Drug Discov. Today* **2011**, *16*, 354–360. [CrossRef]

55. Hosokawa, M.; Nogi, K.; Naito, M.; Yokoyama, T. *Nanoparticle Technology Handbook*, 1st ed.; Hosokawa, M., Nogi, K., Naito, M., Yokoyama, T., Eds.; Elsevier: Amsterdam, The Netherlands, 2007; ISBN 9780444531223.

56. Shende, P.; Patil, S.; Gaud, R.S. A combinatorial approach of inclusion complexation and dendrimer synthesis for effective targeting EGFR-TK. *Mater. Sci. Eng. C* **2017**, *76*, 959–965. [CrossRef] [PubMed]

57. Shi, Y.; Su, C.; Cui, W.; Li, H.; Liu, L.; Feng, B.; Liu, M.; Su, R.; Zhao, L. Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance receptor-positive cancer cells. *J. Nanobiotechnol.* **2015**, *13*, 1–8. [CrossRef] [PubMed]

58. Wang, L.-Z.; Lim, M.Y.-X.; Chun, T-M; Thuya, W.-L.; Nye, P.-L.; Wong, A.; Chan, S.-Y.; Goh, B.-C.; Ho, P.C. Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography–tandem mass spectrometry. *J. Chromatogr. B* **2011**, *897*, 2155–2161. [CrossRef]

59. Fairev, L.; Gomo, C.; Mir, O.; Taief, F.; Schoemann-Thomas, A.; Ropert, S.; Vidal, M.; Dusser, D.; Dauphin, A.; Goldwasser, F.; et al. A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma. *J. Chromatogr. B* **2015**, *33*, 2345–2350. [CrossRef]

60. Kim, M.-J.; Jang, D.-H.; Lee, Y.-I; Jung, H.S.; Lee, H.-J.; Choa, Y.-H. Preparation, characterization, cytotoxicity and drug release behavior of Liposome-enveloped Paclitaxel/Fe3O4 nanoparticles. *J. Nanosci. Nanotechnol.* **2011**, *11*, 889–893. [CrossRef] [PubMed]

61. Mowafy, H.; Alansari, F.; Alsarari, I.; Maghraby, G.; Mohsin, K. HPLC method for determination of Paclitaxel in rabbit plasma. *Asian J. Chem.* **2012**, *24*, 3352–3356.

62. Ma, B.; Zhuang, W.; Liu, G.; Wang, Y. A biomimetic and pH-sensitive polymeric micelle as carrier for Paclitaxel delivery. *Regen. Biomater.* **2018**, *5*, 15–24. [CrossRef] [PubMed]

63. Barbosa, M.V.; Monteiro, L.O.F.; Malagutti, A.R.; Oliveira, M.C.; Carvalho-Junior, A.D.; Leite, E.A. Comparative study of First-derivative Spectrophotometry and High Performance Liquid Chromatography methods for quantification of Paclitaxel in lisosomal formulation. *J. Braz. Chem. Soc.* **2015**, *26*, 1338–1343. [CrossRef]

64. Savale, S. Simultaneous determination of Curcumin and Gefitinib in pure form by using UV spectrophotometric method. *Hygeia J. Drugs Med.* **2017**, *9*, 1–8. [CrossRef]

65. Patel, C.R.; Joshi, K.A.; Pradhan, P.K.; Dey, S.; Upadhyay, U.M. Simultaneous estimation of Simvastatin and Gefitinib in synthetic mixture by Spectrophotometric and HPLC method. *Inven. Rapid Pharm Anal. Qual. Assur.* **2013**, *2013*, 1–7.

66. Kamal, A.H.; El-Malla, S.F.; Hammad, S.F. A review on UV spectrophotometric methods for simultaneous multicomponent analysis. *Eur. J. Pharm. Med. Res.* **2016**, *3*, 348–360.

67. Lam, A.T.N.; Yoon, J.; Ganbold, E.-O.; Singh, D.K.; Kim, D.; Cho, K.-H.; Lee, S.Y.; Choo, J.; Lee, K.; Joo, S.-W. Colloidal gold nanoparticle conjugates of Gefitinib. *Colloids Surf. B Biointerfaces* **2014**, *123*, 61–67. [CrossRef] [PubMed]
68. Lin, Q.; Liu, G.; Zhao, Z.; Wei, D.; Pang, J.; Jiang, Y. Design of Gefitinib-loaded poly (l-lactic acid) microspheres via a supercritical anti-solvent process for dry powder inhalation. *Int. J. Pharm.* 2017, 532, 573–580. [CrossRef] [PubMed]

69. Parashar, P.; Tripathi, C.B.; Arya, M.; Kanoujia, J.; Singh, M.; Yadav, A.; Kaithwas, G.; Saraf, S.A. A synergetic approach for management of lung carcinoma through folic acid functionalized co-therapy of Capsaicin and Gefitinib nanoparticles: Enhanced apoptosis and metalloproteinase-9 down-regulation. *Phytomedicine* 2019, 53, 107–123. [CrossRef]

70. Chu, Q.; Yuan, X.; Ji, W.; Chen, S.; Bao, Y.; Tan, S.; Lu, S.; Wu, K. A novel Paclitaxel-loaded poly(D,L-lactide-co-glycolide)-TWEEN 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment. *Int. J. Nanomed.* 2016, 11, 2119. [CrossRef] [PubMed]

71. Li, F.; Li, J.; Wen, X.; Zhou, S.; Tong, X.; Su, P.; Li, H.; Shi, D. Anti-tumor activity of Paclitaxel-loaded chitosan nanoparticles: An in vitro study. *Mater. Sci. Eng. C* 2009, 29, 2392–2397. [CrossRef]

72. Xu, Z.; Wang, S.; Li, Y.; Wang, M.; Shi, P.; Huang, X. Covalent functionalization of Graphene Oxide with biocompatible Poly(ethylene glycol) for delivery of Paclitaxel. *ACS Appl. Mater. Interfaces* 2014, 6, 17268–17276. [CrossRef]

73. Shen, S.; Wu, Y.; Liu, Y.; Wu, D. High drug-loading nanomedicines: Progress, current status, and prospects. *Int. J. Nanomed.* 2017, 12, 4085–4109. [CrossRef]

74. Govender, T.; Riley, T.; Ehtezazi, T.; Garnett, M.C.; Stolnik, S.; Illum, L.; Davis, S.S. Defining the drug incorporation properties of PLA-PEG nanoparticles. *Int. J. Pharm.* 2000, 199, 95–110. [CrossRef]

75. Chen, W.; Palazzo, A.; Hennink, W.E.; Kok, R.J. Effect of particle size on drug loading and release kinetics of Gefitinib-loaded PLGA microspheres. *Mol. Pharm.* 2017, 14, 459–467. [CrossRef]

76. Magnabosco, G.; Di Giosia, M.; Polishchuk, I.; Weber, E.; Fermani, S.; Bottoni, A.; Zerbetto, F.; Pellici, P.G.; Pokroy, B.; Rapino, S.; et al. Calcite single crystals as hosts for atomic-scale entrainment and slow release of drugs. *Adv. Healthc. Mater.* 2015, 4, 1510–1516. [CrossRef]

77. Maleki Dizaj, S.; Lottipour, F.; Barzegar-Jalali, M.; Zarrintan, M.-H.; Adibkia, K. Box-Behnken experimental design for preparation and optimization of ciprofloxacin hydrochloride-loaded CaCO3 nanoparticles. *J. Drug Deliv. Sci. Technol.* 2015, 29, 125–131. [CrossRef]

78. Falini, G.; Albeck, S.; Weiner, S.; Addadi, L. Control of aragonite or calcite polymorphism by Mollusk Shell Macromolecules. *Science* 1996, 271, 67–69. [CrossRef]

79. Islam, K.N.; Zuki, A.B.Z.; Ali, M.E.; Bin Hussein, M.Z.; Noordin, M.M.; Loqman, M.Y.; Wahid, H.; Hakim, M.A.; Abd Hamid, S.B. Synthesis, characterization, and textural aspects of crossed lamellar layers in Arcidae (Bivalvia, Mollusca) Shells. *Key Eng. Mater.* 2008, 385–389, 672. [CrossRef]

80. Idris, S.B.; Kadir, A.A.; Jesse, F.F.A.; Ramanoon, S.Z.; Basit, M.A.; Zakaria, Z.A.; Zakaria, M.Z.A.B. Synthesis, characterization and in vitro release of oxytetracycline loaded in pH-responsive CaCO3 nanoparticles. *J. Mater. Sci. Eng.* 2013, 2, 1–5. [CrossRef]

81. Almagro, J.; Nikolic, V.D.; Savic, I.M.; Savic, I.M.; Nikolic, L.B.; Stankovic, M.Z.; Marinkovic, V.D. Paclitaxel as an anticancer agent: Isolation, activity, synthesis and stability. *Int. J. Nanomed.* 2015, 10, 2277–2293. [CrossRef]

82. Chemmalar, S.; Abu Bakar, M.Z.; Che Azurahanim, C.A.; Abdul Razak, I.S.; Mohammad Yusof, L.H.; Abdul Razak, N.A. Synthesis and characterization of Gefitinib and Paclitaxel dual drug loaded Cockle shell (*Anadara granosa*) derived Calcium carbonate nanoparticles. *Mater. Sci. Eng. C* 2021, 63. [CrossRef]

83. Eaton, P.; Quaresma, P.; Soares, C.; Neves, C.; de Almeida, M.P.; Pereira, E.; West, P. A direct comparison of experimental methods to measure dimensions of synthetic nanoparticles. *Ultramicroscopy* 2017, 182, 179–190. [CrossRef]

84. Gaument, M.; Vargas, A.; Gurny, R.; Delie, F. Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. *Eur. J. Pharm. Biopharm.* 2008, 69, 1–9. [CrossRef]

85. Hoque, M.E.; Shrehray, M.; Islam, K.N. Processing and Characterization of Cockle shell calcium carbonate (CaCO3) bioceramic for potential application in bone tissue engineering. *J. Mater. Sci. Eng.* 2013, 2, 1–5. [CrossRef]

86. Tanaka, R.; Haramura, M.; Tanaka, A.; Hiyarayama, N. Structure of Gefitinib. *Anal. Sci. X-ray Struct. Anal. Online* 2004, 20, x173–x174. [CrossRef]

87. Nikolic, V.D.; Savic, I.M.; Savic, I.M.; Nikolic, L.B.; Stankovic, M.Z.; Marinkovic, V.D. Paclitaxel as an anticancer agent: Isolation, activity, synthesis and stability. *Open Med.* 2011, 6, 53–56. [CrossRef]

88. Ibiedy, K.M.; Zuki, A.B.Z.; Nurdin, N.; Ajat, M. Combine drug delivery of Thymoquinone-Doxorubicin by Cockle shellderived pH-sensitive aragonite CaCO3 nanoparticles. *Nanosci. Nanotechnol. Asia* 2020, 10, 518–533. [CrossRef]

89. Almagro, I.; Drzymała, P.; Rodriguez-Navarro, A.B.; Sainz-Díaz, C.I.; Willinger, M.G.; Bonarski, J.; Checa, A.G. Crystallography and textural aspects of crossed lamellar layers in Arcidae (Bivalvia, Mollusca) Shells. *Key Eng. Mater.* 2016, 672, 60–70. [CrossRef]

90. Suzuki, M.; Kim, H.; Mukai, H.; Nagasawa, H.; Kagure, T. Quantitative XRD analysis of [110] twin density in biotic aragonites. *J. Struct. Biol.* 2012, 180, 458–468. [CrossRef]

91. Sampath, V.; Huang, P.; Wang, F.; He, D.; Zheng, Z.; Xiao, L.; Ma, C.; Li, C.; Huang, L. Crystalline organization of nacre and crossed lamellar architecture of seashells and their influences in mechanical properties. *Materialia* 2019, 8, 100476. [CrossRef]

92. Bragg, W.L. The structure of aragonite. *Proc. R. Soc. Lond. A* 1924, 105, 16–39. [CrossRef]

93. Yang, B.; Nan, Z. Abnormal polymorph conversion of calcium carbonate from calcite to vaterite. *Mater. Res. Bull.* 2012, 47, 521–526. [CrossRef]
95. Chong, K.Y.; Chia, C.H.; Zakaria, S. Polymorphs calcium carbonate on temperature reaction. AIP Conf. Proc. 2014, 1614, 52–56. [CrossRef]
96. Coates, J. Interpretation of Infrared spectra, A practical approach. In Encyclopedia of Analytical Chemistry; Meyers, R.A., Ed.; John Wiley & Sons, Ltd.: Chichester, UK, 2000; pp. 10815–10837.
97. Andersen, F.A.; Brčević-L. Infrared spectra of amorphous and crystalline calcium carbonate. Acta Chem. Scand. 1991, 45, 1018–1024. [CrossRef]
98. Linga Raju, C.; Narasimhulu, K.; Gopal, N.; Rao, J.; Reddy, B.C. Electron paramagnetic resonance, optical and infrared spectral studies on the marine mussel Arca burnesi shells. J. Mol. Struct. 2002, 608, 201–211. [CrossRef]
99. Nakamoto, K. Infrared and Raman spectra of inorganic and coordination compounds. Handb. Vib. Spectros. 2006, 1872–1892. [CrossRef]
100. Weir, C.E.; Lippincott, E.R. Infrared studies of aragonite, calcite, and vaterite type structures in the borates, carbonates, and nitrates. J. Res. Natl. Bur. Stand. Sect. A Phys. Chem. 1961, 65A, 173. [CrossRef]
101. Ni, M.; Rattner, B.D. Differentiating calcium carbonate polymorphs by surface analysis techniques-an XPS and TOF-SIMS study. Surf. Interface Anal. 2008, 40, 1356–1361. [CrossRef]
102. Weiss, I.M.; Tuross, N.; Addadi, L.; Weiner, S. Mollusc larval shell formation: Amorphous calcium carbonate is a precursor phase for aragonite. J. Exp. Zool. 2002, 293, 478–491. [CrossRef]
103. Simpson, L.J. Electrochemically generated CaCO₃ deposits on iron studied with FTIR and Raman spectroscopy. Electrochem. Acta 1998, 43, 2534–2547. [CrossRef]
104. Weiss, I.M.; Tuross, N.; Addadi, L.; Weiner, S. Mollusc larval shell formation: Amorphous calcium carbonate is a precursor phase for aragonite. J. Exp. Zool. 2002, 293, 478–491. [CrossRef]
105. Talari, A.C.S.; Martinez, M.A.G.; Movasaghi, Z.; Rehman, I.U. Advances in Fourier transform infrared (FTIR) spectroscopy of biological tissues. Appl. Spectrosc. Rev. 2017, 52, 456–506. [CrossRef]
106. Sotomayor, F.J.; Cychosz, K.A.; Thommes, M. Characterization of micro/mesoporous materials by physisorption: Concepts and Case studies. Acc. Mater. Surf. Res. 2018, 3, 34–50.
107. Sing, K.S.W. Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity (Recommendations 1984). Pure Appl. Chem. 1985, 57, 603–619. [CrossRef]
108. Sing, K.S.W. Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity. Pure Appl. Chem. 1982, 54, 2201–2218. [CrossRef]
109. Thommes, M.; Kaneko, K.; Neimark, A.V.; Olivier, J.P.; Rodriguez-Reinoso, F.; Rouquerol, J.; Sing, K.S.W. Physisorption of gases, with special reference to the evaluation of surface area and pore size distribution (IUPAC Technical Report). Pure Appl. Chem. 2015, 87, 1051–1069. [CrossRef]
110. Sing, K.S.W.; Williams, R.T. Physisorption hysteresis loops and the characterization of nanoporous materials. Adsorpt. Sci. Technol. 2004, 22, 773–782. [CrossRef]
111. ud Din, F.; Aman, W.; Ullah, I.; Qureshi, O.S.; Mustapha, O.; Shafique, S.; Zeb, A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int. J. Nanomed. 2017, 12, 7291–7309. [CrossRef] [PubMed]
112. Sun, R.; Zhang, P.; Bajnóczki, E.G.; Neagu, A.; Tai, C.-W.; Persson, I.; Stromme, M.; Cheung, O. Amorphous calcium carbonate constructed from nanoparticle aggregates with unprecedented surface area and mesoporosity. ACS Appl. Mater. Interfaces 2018, 10, 21556–21564. [CrossRef]
113. Manchun, S.; Dass, C.R.; Srimornsak, P. Targeted therapy for cancer using pH-responsive nanocarrier systems. Life Sci. 2012, 90, 381–387. [CrossRef] [PubMed]
114. Ding, Y.; Zhou, Y.-Y.; Chen, H.; Geng, D.-D.; Wu, D.-Y.; Hong, J.; Shen, W.-B.; Hang, T.-J.; Zhang, C. The performance of thiol-terminated PEG-paclitaxel-conjugated gold nanoparticles. Biomaterials 2013, 34, 10217–10227. [CrossRef] [PubMed]
115. Miricioiu, C.; Voicu, V.; Anuta, V.; Tudose, A.; Celia, C.; Paolino, D.; Fresta, M.; Sandulovici, R.; Miricioiu, I. Mathematical modeling of release kinetics from supramolecular drug delivery systems. Pharmaceutics 2019, 11, 140. [CrossRef]
116. Yu, M.; Yuan, W.; Li, D.; Schwedeman, A.; Schwedeman, S.P. Predicting drug release kinetics from nanocarriers inside dialysis bags. J. Control. Release 2019, 315, 23–30. [CrossRef] [PubMed]
117. Ma-Ham, A.; Wu, H.; Wang, J.; Kang, X.; Zhang, Y.; Lin, Y. Apoferritin-based nanomedicine platform for drug delivery: Equilibrium binding study of daunomycin with DNA. J. Mater. Chem. 2011, 21, 8700. [CrossRef]
118. Pingitore, N.E.J.; Fretzdorff, S.B.; Seitz, B.P.; Estrada, L.Y.; Borrego, P.M.; Crawford, G.M.; Love, K.M. Dissolution Kinetics of CaCO₃ in Common Laboratory Solvents. J. Mater. Chem. 2013, 3, 23–30. [CrossRef] [PubMed]
119. Kim, M.-K.; Lee, J.-A.; Jo, M.-R.; Kim, M.-K.; Kim, H.-M.; Oh, J.-M.; Song, N.; Choi, S.-J. Cytotoxicity, uptake behaviors, and oral absorption of food grade calcium carbonate nanomaterials. Nanomaterials 2015, 5, 1938–1954. [CrossRef] [PubMed]
120. Horie, M.; Nishio, K.; Kato, H.; Endoh, S.; Fujita, K.; Nakamura, A.; Kinugasa, S.; Hagihara, Y.; Yoshida, Y.; Iwahashi, H. Evaluation of cellular influences caused by calcium carbonate nanoparticles. Chem. Biol. Interact. 2014, 210, 64–76. [CrossRef]